Review

5-HT Receptors and Temperature Homeostasis

Irina P. Voronova

Department of Thermophysics, Scientific Research Institute of Neurosciences and Medicine, 630117 Novosibirsk, Russia; i.p.voronova@physiol.ru; Tel.: +7-(383)-333-6380; Fax: +7-(383)-335-9754

Abstract: The present review summarizes the data concerning the influence of serotonin (5-HT) receptors on body temperature in warm-blooded animals and on processes associated with its maintenance. This review includes the most important part of investigations from the first studies to the latest ones. The established results on the pharmacological activation of 5-HT1A, 5-HT3, 5-HT7 and 5-HT2 receptor types are discussed. Such activation of the first 3 type of receptors causes a decrease in body temperature, whereas the 5-HT2 activation causes its increase. Physiological mechanisms leading to changes in body temperature as a result of 5-HT receptors’ activation are discussed. In case of 5-HT1A receptor, they include an inhibition of shivering and non-shivering thermogenesis, as well simultaneous increase of peripheral blood flow, i.e., the processes of heat production and heat loss. The physiological processes mediated by 5-HT2 receptor are opposite to those of the 5-HT1A receptor. Mechanisms of 5-HT3 and 5-HT7 receptor participation in these processes are yet to be studied in more detail. Some facts indicating that in natural conditions, without pharmacological impact, these 5-HT receptors are important links in the system of temperature homeostasis, are also discussed.

Keywords: body temperature; serotonin receptor; 5-HT1A; 5-HT2; 5-HT3; 5-HT7

There is no process in an organism independent of the temperature, just as there is no process without heat dissipation. In his monograph, [1] Professor K.P. Ivanov presents astounding calculations by Calver and Prat (1956 cited in [1]): 1 g of human body at 37 °C per unit of time releases heat that is 10,000 times bigger than that released by 1 g of the Sun. “Harmonization” of heat flows escaping the body and coming from outside, ultimately led to the occurrence of an important evolutionary acquisition that allowed vertebrates to spread almost throughout the entire territory of our planet, it being the stability of body temperature (homeothermy). This stability is provided by a wonderful physiological system named the system of thermoregulation [2,3]. Being the youngest homeostatic system of the body in evolutionary terms, the system of thermoregulation, when functioning, uses practically all previously formed organs and tissues, including the mediator systems of the brain.

One of these brain mediator systems is serotonergic. In vertebrate phylogeny, it appears quite early, long before the appearance of homeothermy. In jawless fishes (Cyclostomata), the neurons of the serotonergic system are already well developed [4,5].

Information about the effect of this neuronal system mediator, serotonin (5-HT), on body temperature of warm-blooded animals appeared soon after the discovery of its presence in the brain [6] and in particular in hypothalamus [7]. In 1957, H. Bachtold and A. Pletscher [8] published their data on an increase of rabbit body temperature after intravenous administration of 5-HT. Additionally, in 1961, N. Canal and A. Ornesi (cited in [9]) observed an increase in the body temperature of a rabbit after injecting 5-HT into the cerebral cisterna magna. In 1963, “Nature” published an article written by Feldberg W. and Myers R.D. [10], in which they suggested that body temperature of warm-blooded animals was maintained at a certain level due to “delicate balance in the release of adrenaline, noradrenaline, and 5-HT in the hypothalamus.” After this publication, for more than ten years, there was not a single year without several papers devoted to the effect of 5-HT on body temperature of warm-blooded animals published. Doses of the drug, methods of
administration, experimental animals varied, and the results were different too. By the end of 1980s, several hypotheses were formulated that give preference to the one or the other effect of 5-HT on the processes of maintaining body temperature. Myers (1981) [11], summarizing his works and the works of his colleagues, maintained the opinion about the role of brain 5-HT mainly as a heat production factor. A different point of view was substantiated by other authors [12–15]. According to their opinion, brain 5-HT acts primarily as a heat loss factor. It has also been suggested that the activity of 5-HT structures of the brain determines the set-point of thermoregulation [16], as well as that brain 5-HT is a thermoregulatory reaction modulator, expanding the zone of thermoneutrality in warm-blooded animals [17]. An explanation for this huge amount of conflicting data was found later, precisely—after it was discovered that 5-HT has a number of receptors that sometimes have exactly the opposite effect on body functions.

As of today, 14 types and subtypes of 5-HT receptors have been identified. This is more than any known mediator has got [18,19]. Each of these receptors is characterized by its own amino acid sequence, chromosomal localization, and well-defined structural and functional characteristics. [18–27]. These 14 types of receptors are the molecular basis of the infinite variety of physiological effects that are observed in 5-HT [18,19,28,29]. The change in body temperature of warm-blooded organisms is also one of its physiological effects. 5-HT receptors that definitely influence the body temperature of a warm-blooded organism are the following: the 5-HT receptor of the 1A type (5-HT\textsubscript{1A}), the 5-HT receptor of the 2 type (5-HT\textsubscript{2}), the 5-HT receptor of the 3 type (5-HT\textsubscript{3}), and the 5-HT receptor of the 7 type (5-HT\textsubscript{7}) [18,19,27,30,31]. The present article focuses solely on these receptors and their role in body temperature maintenance of warm-blooded organisms.

1. 5-HT\textsubscript{1A} Receptor

The 5-HT\textsubscript{1A} receptor belongs to the superfamily of the G-protein coupled receptor (GPCR). It is encoded by an intronless gene located on chromosome 5 in humans, on chromosome 13 in mice, and on chromosome 2 in rats [32]. The promoter of the 5-HT\textsubscript{1A} receptor gene (Htr1a) includes some repressor elements [33] that can regulate this gene expression. Moreover, there is evidence that Htr1a transcription can be regulated by glucocorticoids [34–36]. Protein product of this gene consists of 422 amino acids in human and rat and 421 amino acids in mice [32]. After translation, it forms seven transmembrane domains, extracellular N- and intracellular C-terminals. The latter, together with the 3rd intracellular loop, communicates with G-protein. The 5-HT\textsubscript{1A} receptor is bound to the Gi protein, which, after receptor activation, inhibits adenylate cyclase, resulting in a decrease of cyclic adenosine monophosphate (cAMP) formation [37]. These receptors also indirectly open G-protein-gated inwardly rectifying potassium channels (GIRKs) leading to neuron hyperpolarization, and also inhibit the opening of voltage-gated calcium channels [22,26,27,37]. In addition, there is evidence that the 5-HT\textsubscript{1A} receptor can use a variety of non-canonical pathways, such as the extracellular signal-regulated kinase (ERK) signaling pathway, signaling via small G proteins, and some others [26,37]. The way of signal transduction depends on many reasons, among which are the tissue- and region-specificity and also the ability of 5-HT\textsubscript{1A} receptors to form homo- and heterodimers [26,27,38].

5-HT\textsubscript{1A} receptors are widely spread in the organism, both in the peripheral and central nervous systems [19,27]. In the brain, they are found on the neurons of the cortical structures, hippocampus, septum, hypothalamus, midbrain raphe nuclei, and a number of other structures [39–45]. Investigation of their distribution by different methods gave similar results. Moreover, in midbrain raphe nuclei, 5-HT\textsubscript{1A} receptors are also located on 5-HT neurons, i.e., they are autoreceptors (presynaptic or somatodendritic receptors as opposed to postsynaptic ones or heteroreceptors, i.e., the receptors located on non-5-HT neurons) and regulate the activity of the 5-HT system itself [39–41].

5-HT\textsubscript{1A} receptors attract attention of researchers, since they are widespread in the brain, play an important role in the development of the nervous system and its plasticity, affect the functioning of the brain 5-HT system, i.e., are involved in its autoregulation, par-
participate in regulation of many physiological functions, control various behavioral reactions, and are also associated with a number of mental diseases [46]. Moreover, their activation, as a rule, leads to the development of hypothermia in animals at warm ambient temperature.

Indeed, in response to the administration of 8-hydroxy-2-(di-n-propilamino)tetralin (8-OH-DPAT), a selective agonist of 5-HT\textsubscript{1A} receptors, the body temperature of animals at the thermoneutral conditions decreases by about 0.5–3.5 °C (Table 1). Such a decrease is achieved, as a rule, in 10–20 min and does not depend on the route of drug administration. Exceptions are some genetic models, for example, rats specially selected for a reduced hypothermic response after administration of 8-OH-DPAT [45], rats with a high level of aggression [47], some strains of mice [48,49], as well as mice that are genetically modified to lack 5-HT\textsubscript{1A} receptors [50–53].

**Table 1.** Maximal hypothermic effect of selective 5-HT\textsubscript{1A} receptor agonist 8-OH-DPAT in warm-blooded animals.

| Maximal Hypothermic Effect (°C) | Time of Its Achievements (min) | Object | Dose of 8-OH-DPAT | Route of Administration | References |
|--------------------------------|-------------------------------|--------|-------------------|------------------------|------------|
| 3.5                            | 10                            | C57/B16 mice | 3.0 µg | i.c.v.            | [54]       |
| 2.2                            | 30                            | Sprague-Dawley rats | 0.03–0.1 mg/kg | s.c.            | [55]       |
| 2.9                            | 30                            | Sprague-Dawley rats | 0.3 mg/kg | s.c.            | [56]       |
| 3                              | 15                            | C57Bl6 mice | 5 mg/kg | s.c.            | [57]       |
| 3                              | 10                            | Sprague-Dawley rats | 2 µg | i.c.v.            |            |
| 2                              | 30                            | Sprague-Dawley rats | 0.3 mg/kg | s.c.            | [58]       |
| 2.5                            | 30                            | Sprague-Dawley rats | 1 mg/kg | s.c.            | [59]       |
| 2.5                            | 10                            | Hooded Lister rats | 2500 ng | into DRN | [60]       |
| 0.5                            | 60                            | Wistar rats | 0.125 mg/kg | s.c.            | [61]       |
| 0.9                            | 30                            | Wistar rats | 0.25 mg/kg | s.c.            |            |
| 1.5                            | 60                            | Wistar rats | 0.5 mg/kg | s.c.            |            |
| 1.3                            | 30                            | Sprague-Dawley rats | 0.1 mg/kg | s.c.            | [62]       |
| 1.6                            | 10                            | ICR mice | 0.25 mg/kg | s.c.            | [63]       |
| 3.0                            | 15–30                         | Female albino Tuck (T/O strain) mice | 3.0 mg/kg | s.c.            | [64]       |
| 2.3                            | 30                            | Sprague-Dawley rats | 3.0 mg/kg | s.c.            |            |
| 1.3                            | no effect                     | Wistar rats | 5 µg | into DRN into MRN | [9]        |
| 2.5                            | 15                            | Swiss-Webster mice | 2 mg/kg | s.c.            | [65]       |
| 2                              | 20                            | C57/Bl/6Ola mice | 5.0 mg/kg | s.c.            | [66]       |
| 1.3                            | 20                            | C57/Bl/6Ola mice | 0.5 mg/kg | s.c.            | [67]       |
Table 1. Cont.

| Maximal Hypothermic Effect (°C) | Time of Its Achievements (min) | Object | Dose of 8-OH-DPAT | Route of Administration | References |
|---------------------------------|--------------------------------|--------|-------------------|-------------------------|------------|
| 2                               | 15–30                          | Sprague-Dawley rats | 0.25 mg/kg         | s.c.                    | [68]       |
| 2.8                             | 15–30                          | T/O mice female    | 0.5 mg/kg          | s.c.                    |            |
| 1.5                             | 30                             | Wistar rats        | 0.3 mg/kg          | s.c.                    | [69]       |
| 4                               |                                | C57/Bl6 Htr1a (+/+) | 1 mg/kg            | s.c.                    | [70]       |
| 3.3                             |                                | C57/Bl6 Htr1a (+/-) | 1 mg/kg            | s.c.                    |            |
| no effect                       |                                | C57/Bl6 Htr1a (-/-) |                  | s.c.                    |            |
| 1.2                             | 20                             | rats HDS *         | 0.5 mg/kg          | s.c.                    | [45]       |
| 0.7                             |                                | rats RDS *         | 0.5 mg/kg          | s.c.                    |            |
| 2.5                             | 30                             | rats LDS *         | 20 µg              | i.c.v.                   |            |
| 1.27                            | 90                             | Sprague-Dawley rats | 500 µg/kg          | s.c. into the hypothalamus | [71]   |
| 1.15                            |                                | Sprague-Dawley rats | 0.5 µg            | s.c.                    |            |
| 1.6                             | 30                             | Sprague-Dawley rats | 0.05 mg/kg         | s.c.                    | [72]       |
| 3                               |                                | Sprague-Dawley rats | 0.1 mg/kg          | i.p.                    | [50]       |
| 3.5                             |                                | Sprague-Dawley rats | 0.3 mg/kg          | i.p.                    | [72]       |
| 2.1                             | 30                             | 2♂♂ mice 129rSv WT | 0.2 mg/kg          | s.c.                    | [73]       |
| 3.1                             |                                | 2♂♂ Htr1b KO mice | 0.6 mg/kg          | s.c.                    |            |
| 2.5                             | 30                             | Sprague-Dawley rats | 0.1 mg/kg          | s.c.                    | [74]       |
| 2                               | 30                             | Sprague-Dawley rats | 0.3 mg/kg          | i.p.                    | [75]       |
| 0.5                             | 30                             | C57BL/6J mice      | 0.3 mg/kg          | i.p.                    | [75]       |
| 1.2                             |                                | C57BL/6J mice      | 0.6 mg/kg          | i.p.                    |            |
| 1.5                             |                                | C57BL/6J mice      | 0.1 mg/kg          | i.p.                    |            |
| 1.58                            | 30                             | non aggressive rats | 0.5 mg/kg          | i.p.                    | [47]       |
| no effect                       |                                | non-aggressive rats |                 | i.p.                    |            |
| 2.2                             | 30                             | aggressive rats    | 0.5 mg/kg          | i.p.                    | [76]       |
| 0.75                            |                                | C3H mice           | 2 mg/kg            | i.p.                    |            |
| 2                               |                                | Tg8 mice           | 2 mg/kg            | i.p.                    |            |
| Maximal Hypothermic Effect (°C) | Time of Its Achievements (min) | Object | Dose of 8-OH-DPAT | Route of Administration | References |
|--------------------------------|--------------------------------|--------|-------------------|-------------------------|------------|
| 1.75                           | 20                            | CBA/Lac mice | 0.5 mg/kg 1 mg/kg | i.p.                    | [48]       |
| no effect                      | 20                            | AKR mice   | 0.5 mg/kg 1 mg/kg | i.p.                    |            |
| 1.4                             | 30                            | Sprague-Dawley rats | 0.2 mg/kg | i.p.                    | [77]       |
| 1.57                           |                               | CBA/Lac mice |                | i.n.                    |            |
| 1.1                            |                               |              |                  | s.c.                    |            |
| 1.9                             |                               |              |                  |                         |            |
| 0.71                           | 10–20                         | DBA/2 mice  | 1 mg/kg          | i.p.                    |            |
| 1.37                           |                               |              |                  | s.c.                    | [78]       |
| 1.44                           |                               |              |                  |                         |            |
| 1.8                            | i.p.                          | PT mice     |                  |                         |            |
| 1.91                           |                               |              |                  |                         |            |
| 0.98                           |                               |              |                  |                         |            |
| 0.67                           |                               |              |                  |                         |            |
| 2.62                           |                               |              |                  |                         |            |
| 1.2                             |                               | CBA/Lac mice |                  |                         |            |
| 1.0                             |                               | C57Bl mice  |                  |                         |            |
| 2.2                             |                               |              |                  |                         |            |
| 0.5                             |                               |              |                  |                         |            |
| 1.2                             | 20                            | 1A-High mice | 0.5 mg/kg        | i.p.                    |            |
| 1.0                             | 10                            | 1A-Low mice |                  |                         |            |
| 2.25                           |                               |              |                  |                         |            |
| 2.5                             |                               |              |                  |                         |            |
| 0.4ns                           |                               |              |                  |                         |            |
| 1.25                           |                               |              |                  |                         |            |
| 2.5                             | 30                            | CBA/Lac mice | 40 nM            | i.c.v.                  | [80]       |
| 1.2                             |                               |              |                  |                         |            |
| 0.9                             |                               |              |                  |                         |            |
| 2.2                             |                               |              |                  |                         |            |
| 0.5ns                           |                               |              |                  |                         |            |
| 0.5ns                           |                               |              |                  |                         |            |
| 1.2                             |                               |              |                  |                         |            |
| 2.6                             |                               |              |                  |                         |            |
| 3                               | 20                            | WT mice     | 0.5 mg/kg        | i.p.                    | [52]       |
| 1.3                             |                               | KO Htr1a in DRN |      |                         |            |
| 1.75                           | 20                            | ♂ WT mice   | 0.75 mg/kg       | i.p.                    | [53]       |
| no effect                       |                               | ♀ WT mice   |                  |                         |            |

Note: 8-OH-DPAT—(±)-8-Hydroxy-2-(dipropylamino)tetrinal; i.c.v.—intracerebroventricular; s.c.—subcutaneous; i.p.—intraperitoneal; i.v.—intravenous; i.n.—intranasal; DRN—dorsal raphe nucleus; MRN—median raphe nucleus; ns—not significant. *—Rats with high (HDS), low (LDS), and random (RDS) hypothermic responses to the 5-HT_{1A} receptor agonist 8-OH-DPAT. If it is not indicated specially, only the male were used in the experiments.
Goodwin et al. in 1985 [54] have posed a quite natural question about the central or peripheral origin of the 8-OH-DPAT hypothermic effect. They compared the effects of peripheral (0.25–10 mg/kg s.c.) and central (3 µg i.c.v) drug administration. (According to the authors’ calculations, taking into account the weight of the animal, 3 µg corresponds to 100–120 µg/kg). They found that the central administration of a lower dose led to a faster and deeper drop in body temperature, and concluded that the effect was of central origin. Later, other researchers came to the same conclusion [56,81]: Bagdy and To [81] comparing the effects of central and peripheral administration of 8-OH-DPAT, Gudelsky et al. [56] using xylamidine- an antagonist of 5-HT receptors that does not penetrate the blood–brain barrier.

Goodwin et al. [54] in the same article made an assumption, supported later by a number of other authors, that the hypothermic effect of 5-HT$_{1A}$ activation with 8-OH-DPAT “might serve as a simple physiological means of studying central serotonergic mechanisms in vivo” [54,55,61,65]. At present, this effect is generally recognized and is widely used both for assessing the functional activity of 5-HT$_{1A}$ receptors [47,82] and the comparative characterization of newly created ligands to these receptors [50,83]. Development of gene engineering opened a new side using the hypothermic effect of 5-HT$_{1A}$ activation: its absence confirms successful knock-out of Htr1a [52,70].

As 5-HT$_{1A}$ receptors are located in different regions of the brain and also on 5-HT neurons (i.e., are post- and presynaptic), Hjort et al. [84] made the suggestion that pre- and postsynaptic receptors may differ in their properties. So, it is not surprising that in the scientific world, the question arose about the localization of 5-HT$_{1A}$ receptors involved in the realization of the hypothermic effect that occurs after their activation. Thus, repeated attempts have been made to shed light on this problem (Table 2).

**Table 2.** Results of investigations of localization of 5-HT$_{1A}$ receptors mediating the 8-OH-DPAT-induced hypothermia.

| Conclusion | Argumentation | Object | References |
|------------|---------------|--------|------------|
| Pre-       | Hypothermic effect of 8-OH-DPAT was attenuated when 5-HT was depleted by repeated i.p. administration of pCPA or by injection of 5,7-DHT into the third ventricle | C57/B16/0la mice | [54] |
| Post-      | After pretreatment by pCPA the minimal dose of 8-OH-DPAT (0.03 mg/kg s.c.), ineffective earlier, deveined effective. It may be the result of receptor sensitization that appeared after pCPA reducing of the whole brain 5-HT level. | Sprague-Dawley rats | [55] |
| Pre-       | Hypothermic effect of 8-OH-DPAT was attenuated when 5-HT was depleted by repeated i.p. administration of pCPA or by injection of 5,7-DHT into the third ventricle | Sprague-Dawley rat | [58] |
| Post-      | pCPA tended to increase the hypothermic effect of 8-OH-DPAT (−3 °C in comparing with −2.5 °C) | Sprague-Dawley rats | [59] |
| Post-      | pCPA tended to increase the hypothermic effect of 8-OH-DPAT | ddY mice | [85] |
| Pre-       | Lesioning of central 5-HT neurones by 5,7-DHT abolished the hypothermic response to 8-OH-DPAT. Depletion of brain 5-HT levels with p-CPA markedly attenuated the hypothermic response. | Female albino Tuck (T/O strain) mice | [64] |
| Conclusion         | Argumentation                                                                 | Object                  | References |
|-------------------|-------------------------------------------------------------------------------|-------------------------|------------|
| Post-             | Lesioning of central 5-HT neurones by 5,7-DHT had no effect on the hypothermic responses to lower doses of 8-OH-DPAT. pCPA significantly increased hypothermic response. | Sprague-Dawley rats    | [64]       |
| Pre-Post-(?)      | Injection of 8-OH-DPAT directly into the DRN evoked a clear hypothermic effect. Injection of 8-OH-DPAT directly into the MRN produced no hypothermic effect. | Wistar rat              | [9]        |
| ?                 | pCPA pretreatment reduced the 5-HT level in cortex and hippocampus, but did not affect the hypothermia | Swiss-Webster mice      | [65]       |
| Pre-              | Destruction of 5-HT neurones with the neurotoxin 5,7-DHT abolished the hypothermic response to 8-OH-DPAT | C57/Bl/601a mice        | [66]       |
| Post-             | Dose–response curve shows that i.c.v. administration of 8-OH-DPAT was more potent than direct injection to the DRN to causing hypothermia. | Sprague-Dawley rats     | [81]       |
| ?                 | Correlation between the severity of hypothermic response to 8-OH-DPAT and radio ligand 5-HT_{1A} binding sites in the brain regions associated with thermoregulation was not found | rats HDS * rats LDS *   | [45]       |
| Post-             | Buspirone produced the same significant increase in prolactin and growth hormone (effects mediated by post- 5HT_{1A} receptors) in the tryptophan-depleted state as in the control condition. The degree of hypothermia produced by buspirone was not significantly different in the two experimental conditions. | healthy volunteers humen | [86]       |
| Pre-              | *Htr1a* auto-KO mice displayed no detectable body temperature decrease in response to 8-OH-DPAT | Genetically modified mice | [53,87]    |
| Pre-              | *Htr1a* hetero-KO mice displayed a full hypothermic response to 8-OH-DPAT | Genetically modified mice | [87]       |

Note: The table does not include the data of O’Connell et al. [88], as well as a number of other authors, despite the promising titles of their works. O’Connell et al. (1992) [88] used in their study the substance BMY7378, which, as was showed later, was primarily an antagonist of α-adrenergic receptors (IUPHAR / BPS Guide to Pharmacology) [89]. So it is possible that the observed effects of this compound were the results of its action on adrenergic, but not 5-HT receptors. 8-OH-DPAT—(±)-8-Hydroxy-2-(dipropylamino)tetralin; pCPA—para-chlorophenylalanine; 5,7-DHT—5,7-dihydroxytryptamine; i.p.—intraperitoneal; s.c.—subcutaneous; i.c.v.—intracerebroventricular; DRN—dorsal raphe nucleus; MRN—median raphe nucleus; Post-(?)—role of post-synaptic receptors is not completely excluded; ?—no defined answer; *—Rats with high (HDS) and low (LDS) hypothermic responses to the 5-HT_{1A} receptor agonist 8-OH-DPAT.

Depletion of the neuronal 5-HT pool by para-chlorophenylalanine (pCPA) [90], as well as the destruction of 5-HT neurons by neurotoxin 5,7-dihydroxytryptamine (5,7-DHT) were the tools most often used to address this issue. A reduction in hypothermic response after pCPA administration indicates a dependence upon endogenous 5-HT stores, presynaptic receptor localization, affecting 5-HT synthesis and/or release, is therefore inferred. Conversely, if the receptor is postsynaptic a reduction in mediator availability might be expected to result in an adaptive receptor upregulation, yielding a supersensitive response. In the experiments with such protocols, Hjorht [55] observed a clear hypothermic effect when using a low dose of 8-OH-DPAT (0.03 mg/kg), which was ineffective without prior administration of pCPA. According to these results, he concluded that post-
synaptic 5-HT<sub>1A</sub> receptors mediated the hypothermic response. The same conclusion was reached by Hudson et al. [59] as well as Matsuda et al. [85], who obtained similar results. Meller et al. [65], despite the use of multiple doses of both pCPA and 8-OH-DPAT, did not receive any changes in the hypothermic response and, subsequently, the answer to the question posed. Goodwin et al. [54,58] also pretreated animals with pCPA, but observed the disappearance of the 8-OH-DPAT hypothermic effect, from this they concluded that hypothermia is caused by presynaptic receptors. In studies of these authors an even more compelling argument in favor of presynaptic receptors was the disappearance of the 8-OH-DPAT effect after the destruction of 5-HT neurons by 5,7-DHT. Bill et al. [64], using the same methods, confirmed the findings of Goodwin et al. [54] in mice, and obtained opposite results in rats. As a possible reason for inconsistency in their results with the results of Goodwin et al. [58], the authors suggested the difference in doses of the drug used. Hillegaart [9] was also prone to the conclusion that the participation of presynaptic 5-HT<sub>1A</sub> receptors in the realization of hypothermia. She injected 8-OH-DPAT directly into the region of 5-HT neurons localization (dorsal raphe nucleus, DRN) and observed a clear hypothermic effect, although she did not dare to completely exclude the role of postsynaptic receptors. Bagdy and To [81] compared the effects of different doses of 8-OH-DPAT injected i.c.v. with the results of Hillegaart [9] (see earlier) and concluded that receptors in the close vicinity of the lateral ventricle (i.e., post-synaptic) may play a predominant role in hypothermic response. An attempt to find out whether pre- or post-synaptic 5-HT<sub>1A</sub> receptors are involved in the development of hypothermia in humans was undertaken by Blier et al. [86]. They offered to volunteers a tryptophan-free diet (to lower 5-HT levels in the brain), followed by buspirone (5-HT<sub>1A</sub> receptor agonist). The researchers did not receive any differences between the control and experimental groups of volunteers both in the temperature response to 5-HT<sub>1A</sub> receptors or in the endocrine responses mediated by post-synaptic 5-HT<sub>1A</sub> receptors. From these results, the authors concluded that the hypothermic response after 5-HT<sub>1A</sub> receptors’ activation in humans was also mediated by a post-synaptic mechanism. Knapp et al. [45] bred strains of rats different in sensitivity to 8-OH-DPAT. The selection was based on the severity of hypothermia in response to the administration of this drug. As a result, lines with high (HDS) and low (LDS) sensitivity were obtained. In rats of six to ten generations, the researchers conducted a radioligand study of 5-HT<sub>1A</sub> receptors in the animal brains and tried to compare the number of receptor binding sites in different areas with the severity of hypothermia. Significant differences in binding were found in specific limbic cortical projection sites, with the HDS line having the greatest density of sites. Body temperature responses correlated significantly with [<sup>3</sup>H]8-OH-DPAT receptor binding only in a few areas of frontal cortex. Binding in many other brain regions, including anterior and posterior hypothalami (regions long associated with body temperature regulation) and raphe showed no significant differences among the lines. Thus, the attempt undertaken by Knapp et al. [45] did not provide a clear-cut answer.

Impressive results in deciding which pre- or post-synaptic receptors mediate the hypothermic effect of 8-OH-DPAT were obtained using genetic engineering methods [53,87]. The authors of these studies created mice lacking pre- or post-synaptic 5-HT<sub>1A</sub> receptors. When investigating 5-HT<sub>1A</sub> receptor activation, they found that Htr1a auto-KO mice displayed no detectable body temperature decrease in response to 8-OH-DPAT [53,87]. On the other hand, Htr1a hetero-KO mice displayed full hypothermic response to 8-OH-DPAT [87]. Based on the results of these authors, it can be argued that the hypothermic effect of 5-HT<sub>1A</sub> receptor activation, at least in mice, is mediated by presynaptic receptors.

In the end of the discussion on the role of pre- and postsynaptic receptors in the hypothermic effect of 5-HT<sub>1A</sub> receptors’ activation by 8-OH-DPAT, it is necessary to mention the results of Hjorth and Magnusson [41]. These authors convincingly showed that 8-OH-DPAT acts on presynaptic receptors located on the bodies of 5-HT neurons. In their experiments, after unilateral axonectomy of the ascending pathways from 5-HT neurons, systemic 8-OH-DPAT administration changed the synthesis and release of 5-HT in the region of terminals only at the intact side.
It would be also interesting to discuss the following, which physiological processes lead to hypothermia in a warm-blooded animal after 5-HT<sub>1A</sub> receptors' activation.

The hypothesis that the cause of a decrease in body temperature in an animal after 5-HT<sub>1A</sub> receptors' activation by 8-OH-DPAT is the heat loss processes was made by Hjorth in 1985 [55]. He referred to his own unpublished observations: body temperature did not decrease when experiments were carried out at an ambient temperature of 32 °C. In the same year, Goodwin et al. [54] published data on the development of the hypothermic effect at different ambient temperatures. The decrease of body temperature in an animal after 5-HT<sub>1A</sub> receptors' activation by 8-OH-DPAT was lesser in higher ambient temperature. The authors made a logical conclusion that the difficulty in heat dissipation prevented the development of the hypothermic effect of 5-HT<sub>1A</sub> receptors' activation. Therefore, it is the heat loss from the surface of the body that is the reason for the occurrence of hypothermia.

A more detailed study was carried out by Lin et al. [71]. They recorded not only body temperature being an integral parameter, but also oxygen (O<sub>2</sub>) consumption, by which they estimated the heat production of the organism, skin temperature, by which they assessed convective heat loss, as well as water vapor content in expired air, on the basis of which evaporative heat loss was calculated. The experiments were carried out at room temperature. 5-HT<sub>1A</sub> receptors activation was performed by injecting 8-OH-DPAT s.c. (500 µg/kg) or directly into hypothalamus (0.5 µg). Despite the different route of drug administration, the results were similar: in animals, along with a decrease in body temperature, metabolic rate reduced, and heat loss from the body surface increased. Thus, the evidence was obtained that the processes of both heat loss and heat production were involved in the appearance of hypothermic response to 5-HT<sub>1A</sub> receptors activation. In our experiments performed on mice CBA [80], we also observed the development of hypothermic response accompanied by a significant decrease in heat production (estimated by O<sub>2</sub> consumption) after 5-HT<sub>1A</sub> receptors' activation (40nM of 8-OH-DPAT, i.c.v.), although an increase in heat loss (estimated by tail skin temperature) was non-significant.

Estimation of the heat loss by the measurement of the skin temperature in the areas that are considered to be responsible for this process (for example, ears and tail in rodents, ears in rabbits) [91–97] is a classic technique in physiology of thermoregulation. An increase in skin temperature indicates a vasodilation, a decrease—a blood vessel constriction. The speed of blood flow in given areas also changes. Its changes occur in parallel with constriction or dilation of blood vessels and are reflected in changes of skin temperature. Lin et al. [71] evaluated heat loss from the change in skin temperature on the rat paw. Direct measurements of blood flow in areas responsible for heat loss upon 5-HT<sub>1A</sub> receptors activation were carried out by Blessing [98] in collaboration with Ootsuka [99–101]. In the experiments of these authors, blood flow in the rabbit pinna, initially reduced in response to cooling or pyrogen treatment, returned to normal values after 8-OH-DPAT administration. Administration of selective 5-HT<sub>1A</sub> receptor antagonist N-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]-N-pyridin-2-ylcyclohexanecarboxamide (WAY-100635) canceled the effect of 8-OH-DPAT. In the same experiments, Ootsuka and Blessing [99–101] discovered another interesting fact: the effect of 5-HT<sub>1A</sub> receptors on the activity of sympathetic nerves mediating vascular tone [99]. It is known that exposure to cold is accompanied by the activation of the sympathoadrenal system [102–104]. 5-HT<sub>1A</sub> receptors activation decreased the activity of vasomotor sympathetic nerves to about 5% of their initial level in warmth [99], and also significantly inhibited the discharge of these nerves during cooling [99–101]. At the same time, 8-OH-DPAT, administered peripherally, did not change nerves discharge evoked by electrical stimulation of preganglionic sympathetic axons in cervical sympathetic trunk. Based on these results, the authors concluded that the sympathoinhibitory action of this compound is realized within the central nervous system (CNS), and not peripherally. In other words, 5-HT<sub>1A</sub> receptors that inhibit the activity of sympathetic vasomotor nerves are found in the CNS pathways normally activating cutaneous sympathetic vasomotor nerves in response to cold.
Heat production in the organism is carried out continuously by all organs and tissues. However, in emergency cases, when it must be increased to maintain constant body temperature of a warm-blooded organism (for example, at exposure to cold), oxidative processes in tissues, and primarily in brown adipose tissue (BAT), increase. Moreover, special forms of muscle contractile activity arise: so-called muscle thermoregulatory tone and shivering [2,3,105–109]. BAT is a special type of adipose tissue. Its main function is considered to be heat production (non-shivering thermogenesis) [110–112]. A study of the effect of 5-HT_{1A} receptors on thermogenesis in BAT was undertaken by Ootsuka and Blessing [101]. In their experiments, the authors initiated thermogenesis by exposure to cold, and assessed it by the change in temperature of BAT. 5-HT_{1A} receptors activation by administration of 8-OH-DPAT inhibited thermogenesis in BAT. Morrison [113] investigated thermogenesis in BAT initiated by leptin administration and also found that activation of 5-HT_{1A} receptors inhibited thermogenesis. Studies on 5-HT_{1A} receptors’ role in modulating sympathetic influences on BAT thermogenesis have revealed their inhibitory role in these processes as well. A decrease in sympathetic impulses in BAT was recorded both with peripheral [101,114] and with central [114,115] administration of 8-OH-DPAT. Mota et al. [114] concluded that rostral raphe pallidus played an important role in the inhibition of BAT sympathetic nervous activity (SNA) by 5HT_{1A} receptor. They found that microinjections of WAY100635 into this area prevented changes caused by 8-OH-DPAT and this prevention took place both when 8-OH-DPAT was injected exactly into this area, and intravenously. Previously, the significance of this region as a key region in the onset of hypothermia caused by 5-HT_{1A} receptors activation was declared [77]. Further studies revealed that inhibition of 5-HT_{1A} receptors in warm environment by WAY100635 injected into the rostral raphe pallidus led to an increase in BAT SNA [114]. From this, the authors concluded that under a warm condition, “there is tonic activation of 5HT_{1A} receptors in the rostral raphe pallidus that contributes to the warm-evoked inhibition of BAT SNA and BAT thermogenesis” [114].

Another source of heat production, especially important under exposure to cold, is the so-called shivering thermogenesis—heat production in skeletal muscles by specific types of its activity—shivering and thermoregulatory tone [116–119]. As it turned out, 5-HT_{1A} receptors have an inhibitory effect on this source of heat production too. In the experiments of Berner et al. [120] at an ambient temperature of 15–20 °C (conditions capable of causing shivering), 8-OH-DPAT, injected into the nucleus raphe magnus, dose-dependently reduced the temperature of the preoptic region of hypothalamus, total metabolism assessed by O_{2} consumption, and shivering assessed by the electrical activity of the neck muscles. The inhibitory effect of 5-HT_{1A} receptors on shivering thermogenesis was also confirmed in other experiments: during dialysis of 8-OH-DPAT into the paragigantocellularis lateralis region, a medullary region lateral to the midline raphe’ that contains 5-HT neurons [121], and into the medullary raphe’ region [122].

The effects of 5-HT_{1A} receptors activation on thermoregulatory reactions of a warm-blooded organism are summarized in Table 3. It can be seen that 5-HT_{1A} receptor’s activation affects both heat production and heat loss processes, changes in which together lead to the well-known phenomenon—hypothermia of warm-blooded organisms under the activation of these receptors. The influence of 5-HT_{1A} receptors (at least on blood flow and thermogenesis in BAT) is realized via their effects on the activity of sympathetic nerves (see earlier).
Table 3. Effect of 5-HT<sub>1A</sub> receptor activation by its selective agonist 8-OH-DPAT on thermoregulatory responses in warm-blooded organisms.

| Change in Thermoregulatory Response | Change in Registered Parameter | Ambient Temperature Conditions | Object | Dose and Route of Administration | References |
|------------------------------------|--------------------------------|--------------------------------|--------|----------------------------------|------------|
| **↓ General metabolism**            | **↓O<sub>2</sub> consumption** | Room temperature               | rat    | 500 µg/kg s.c.                   | [71]       |
|                                    |                                |                                | rat    | 0.5 µg into the hypothalamus     | [71]       |
|                                    |                                |                                | mice   | 40 nM left lateral ventricle     | [80]       |
|                                    | **↓excretion of CO<sub>2</sub>** |                                | rat    | 10 mM 60 nL raphe' pallidus      | [113]      |
|                                    | increased via leptin injection |                                | rat    | 4 mg/mL 1 µL Nucleus raphe' magnus | [120]      |
|                                    | **↓O<sub>2</sub> consumption** | Cooling                        | rat    | 10 mM 60 nL Rostral raphe' pallidus | [115]      |
|                                    | **↓excretion of CO<sub>2</sub>** |                                | rat    | 100 µg/500 µL i.v.               | [114]      |
|                                    |                                |                                | rat    | 10 mM 60 nL Rostral raphe' pallidus | [114]      |
|                                    |                                |                                | rat    | 60 nL Rostral raphe' pallidus    | [112]      |
|                                    |                                |                                | rat    | 500 µg/kg s.c.                   | [71]       |
|                                    | **↑ skin temperature**         | Room temperature               | rat    | 0.5 µg into the hypothalamus     | [71]       |
|                                    | **↑ peripheral blood flow**    |                                | rabbit | 0.1 mg/kg i.v.                   | [98]       |
|                                    |                                |                                | rabbit | 0.1 mg/kg i.v.                   | [99]       |
|                                    |                                |                                | rabbit | 3–5 nmol rostral medullary raphe' | [100]      |
|                                    |                                |                                | rat    | 0.5 mg/kg, s.c.                  | [101]      |
|                                    |                                |                                | piglet | dialysis 30 mM 30 min medullary raphe' | [122]      |
|                                    |                                |                                | rat    | 0.6 µmol/kg s.c.                 | [123]      |
| **↑ Heat loss**                    | **↑BAT temperature**           | Room temperature               | rat    | 10 mM 60 nL Rostral raphe' pallidus | [113]      |
|                                    | increased via leptin injection |                                | rat    | 4 mg/mL 1 µL Nucleus raphe' magnus | [120]      |
|                                    | **↓ shivering, i.e., muscle electrical activity** |                                | rat    | 10 mM 60 nL Rostral raphe' pallidus | [115]      |
|                                    |                                |                                | rat    | 0.5 mg/kg, s.c.                  | [101]      |
|                                    |                                |                                | rat    | 100 µg/500 µL i.v.               | [114]      |
|                                    | **↓ BAT temperature**          | Cooling                        | rat    | 10 mM 60 nL Rostral raphe' pallidus | [114]      |

Note: ↓—decrease of parameter; ↑—increase of parameter.
After experiments of Goodwin et al. [54], the effects of 5-HT_{1A} receptor activation by 8-OH-DPAT are considered as central, regardless of the route of drug administration. The central administration of 5-HT_{1A} receptors ligands is used, as a rule, in order to reveal the role of specific regions of the CNS in the reactions mediated by these receptors. Madden and Morrison [124,125] drew attention to the 5-HT_{1A} receptor in the spinal cord. They discovered that 5-HT_{1A} receptors in the spinal intermediolateral nucleus could take place in regulation of BAT SNA and thermogenesis induced by this activity, but their effect was opposite to that of brain 5-HT_{1A} receptors. Thus, there is no doubt that more detailed studies of the role of 5-HT_{1A} receptors from different CNS areas and their share in regulation of physiological functions of the body are required.

It is worth emphasizing that all the above-described data show evidence only of the POTENTIAL role of 5-HT_{1A} receptors in thermoregulatory reactions, since all the results are the responses to pharmacological impact on receptors. However, it would be interesting to find out whether these receptors are involved in thermoregulatory reactions in natural conditions or in conditions nearest to the natural ones. Such an attempt was made [126]. As a model of temperature action, the model of long-term adaptation to cold (four to six weeks at a temperature of 4–6 °C) according to Hart [127] was chosen. This model is well studied from the point of view of thermoregulation. In particular, with its use, changes in the characteristics of neurons in midbrain [128] and hypothalamus [129,130] were revealed in animals adapted to cold compared to control ones. Since the neurons in the brain stem, as well as most thermosensitive neurons in hypothalamus, are able to respond to microinjections of 5-HT [131,132], i.e., have 5-HT receptors in their structure, it was hypothesized that these receptors could participate in changes of neurons characteristics after adaptation to cold. For the 5-HT_{1A} receptor, a good correspondence between the mRNA level of its gene and the number of its protein molecules (or sites of specific radioligand binding) in different parts of the brain was shown [19,27,42]. So, the change in the number of 5-HT_{1A} receptors can be judged with a high degree of probability by the change in the mRNA level of its gene. Based on these conclusions, it was decided to evaluate the effect of long-term exposure to cold on the 5-HT_{1A} receptor in the brain by the expression of its gene. However, changes in the 5-HT_{1A} receptor mRNA level in the studied brain regions (cortex, hippocampus, hypothalamus) after prolonged exposure to cold were not observed [126]. It is possible that changes could be found in other brain structures or using other models of temperature exposure.

However, some works supporting the role of the 5-HT_{1A} receptor in body temperature regulation in warm-blooded animals during natural body reactions without pharmacological influence can be cited. This is indirectly evidenced by electrophysiological studies of brain neurons. Thus, it was found that the majority of raphe obscurus thermosensitive 5-HT neurons decrease the frequency of their discharges upon exposure to heat and increase it upon cooling (2/3 and 3/4 of neurons, respectively) [133]. Nason and Mason [134] in the medullary raphe also observed increased discharge of the cells, which they identified as 5-HT ones, in response to cold. It is possible that an increase in the discharge of 5-HT neurons in response to cold indicates a possible decrease in the activity of presynaptic 5-HT_{1A} receptors, which, as it is known (see earlier), contributes to the development of hypothermia. Conversely, a decrease in the discharge of 5-HT neurons in response to heating may indicate an increase in the activity of these receptors and the development of reactions that prevent overheating.

When studying 5-HT_{1A} receptor gene expression in ground squirrels at diverse stages of hibernation–waking cycle, a decrease in the mRNA level of this receptor in the midbrain during arousal of animals was found [135]. Arousal from hibernation is a very active process when body temperature of an animal rises in just a few hours from the values slightly higher than 0 °C to the value of normal body temperature in warm-blooded animals [136]. A decrease in the 5-HT_{1A} mRNA level (and, presumably, the amount of the receptor itself, the activation of which contributes to the development of hypothermia) upon arousal of animals from hibernation seems to be a quite reasonable physiological reaction.
Moreover, there is evidence that genetic modification of this receptor affects body temperature in mutant mice. Kusserow et al. [137] reported that in home cage body temperature in male mice with 5-HT$_{1A}$ receptor gene overexpression is lower in comparison with wild type (WT) mice. In mice with Htr1aKO, stress-induced hyperthermia is higher than in mice of the corresponding WT: 2.5 and 1.5 °C, respectively [138,139]. The stressing factors in these experiments were the placement of animals in a new cage or the injection of saline. In both cases, i.e., regardless of the type of stress, temperature responses were similar: the increase in body temperature in KO mice was greater than in WT mice. Richardson-Jones [51] found, that in mice with high and low 5-HT$_{1A}$ receptor levels, temperature response to a new cage was different: body temperature in mice with the low 5-HT$_{1A}$ receptor level elevated more than in mice with the high 5-HT$_{1A}$ receptor level. These results directly indicate that the absence (or deficiency) of one of the elements of the thermoregulatory system—the 5-HT$_{1A}$ receptor—can lead to serious shifts in the maintenance of the body temperature balance. In this case, the absence of the 5-HT$_{1A}$ receptor, the activation of which contributes to a decrease in body temperature, leads to the development of more pronounced hyperthermia. It is important to note that the difference in body temperature of mice described by Olivier et al. [138], Toth [139], and Richardson-Jones [51] arises under stress. In a calm state, when animals are in their home cage, without any external influences on them, there is no difference in body temperature. This example perfectly illustrates the necessity of choosing an adequate model for physiological experiment.

Thus, under the pharmacological activation of the 5-HT$_{1A}$ receptor, reactions contributing to a decrease in heat production and an increase in heat loss develop. This leads to reduction in body temperature. These reactions are carried out with the involvement of the sympathetic nervous system. There are the facts indicating that in natural conditions, without pharmacological influence, the 5-HT$_{1A}$ receptor is an important link in the system of temperature homeostasis. There is no data that could elucidate the possible changes in the receptors themselves during the processes of thermoregulation.

2. 5-HT$_2$ Receptors

5-HT$_2$ receptors are another type of 5-HT receptors that can influence the body temperature in warm-blooded organisms. It should be emphasized that all three receptor subtypes: 5-HT$_{2A}$, 5-HT$_{2C}$, and 5-HT$_{2B}$—may participate in this impact. Although in relation to the latter there is no direct evidence that its activation changes body temperature of an animal, its participation in metabolic processes (see below) suggests its imminent appearance.

5-HT$_2$ receptors, as well as most 5-HT receptors, are metabotropic, i.e., they carry out their function through the G-protein, with which they are coupled. Nevertheless these receptors differ significantly from the other 5-HT receptors by secondary messengers. Most metabotropic 5-HT receptors realize their action through cAMP, inhibiting its activity (such as 5-HT$_{1A}$ receptors) or, conversely, activating it (such as 5-HT$_7$ receptors). In 5-HT$_2$ receptors, secondary messengers are mainly phospholipases: the “canonical”—phospholipase C (PLC) and “noncanonical”—phospholipase A2 (PLA2) and phospholipase D (PLD), as well as extracellular signal-regulated kinase (ERK), which can participate in signal transduction from other 5-HT receptors too, being also a “noncanonical” mediator for them [26]. In addition, 5-HT$_{2B}$ receptors can transduce a signal by activating nitric-oxide synthases—constitutive and inducible [27].

5-HT$_2$ receptors gene structures’ comparison made it possible to conclude that the most ancient 5-HT$_2$ receptor subtype is 5-HT$_{2B}$, from which 5-HT$_{2A}$ and 5-HT$_{2C}$ subtypes subsequently originated [140].
All three types of 5-HT$_2$ receptors are widespread both in the brain and the periphery [26]. Earlier, it was thought that 5-HT$_{2B}$ was absent in the brain [141] later its presence was discovered. In general, for 5-HT$_2$ receptors, as well as for other 5-HT receptors, the distribution of specific receptor binding sites (i.e., protein molecules of 5-HT receptors), with rare exceptions, corresponds to the distribution of their mRNA. In the brain, 5-HT$_{2A}$ (along with 5-HT$_{1A}$) is widely distributed [26], especially in comparison with the number of other 5-HT receptors. However, judging by the mRNA level, 5-HT$_{2C}$ is the most abundant 5-HT receptor in the brain [142]. Nevertheless, one should always take into account the local distribution of receptors in the brain regions. 5-HT$_{2A}$ receptors have high density in forebrain: in cortex, hippocampus, basal ganglia. The highest level of 5-HT$_{2C}$ receptor mRNA was found in choroid plexus, hippocampus, and subthalamic and lateral habenular nuclei [143–145], its rather high level was observed in median raphe, as well as in hypothalamus [26]. In hypothalamus, the Htr2c mRNA level is an order of magnitude higher than mRNA levels of other 5-HT receptors [146].

5-HT$_{2A}$ receptors’ gene expression regulation is carried out by numerous promoter sites such as cAMP-response element, glucocorticoid receptor binding site [148], and others. 5-HT$_{2B}$ and 5-HT$_{2C}$ receptors’ mRNA is capable of forming splicing variants [149,150]. In addition, the 5-HT$_{2C}$ receptor gene is characterized by the presence of sites at which its mRNA can be edited [151–154]. To this date, among all known GPCRs, the 5-HT$_{2C}$ receptor is the only one for which mRNA editing has been proven [27,150]. In total, there are 32 editing permutations in the 5HT$_{2C}$ receptor transcript encoding 24 receptor proteins [27,150,155]. The edited 5-HT$_{2C}$ receptor binds worse to the G-protein leading to a decrease in receptor activity. It is possible that RNA editing is a way of receptor activity regulation [27,150–156], although such regulation at the level of the whole organism requires strong physiological evidence.

Studies of mice with 5-HT$_2$ receptors genes knockout indicate the participation of these receptors in the vital processes of the body. Thus, 5-HT$_{2B}$ knockout is associated with severe cardiac abnormalities and embryonic and postnatal lethality [26]. 5-HT$_{2C}$-knockout mice have decreased general metabolism and altered expression of some mitochondrial genes in comparison with WT mice [157].

Different ways for 5-HT$_2$ receptors’ activity regulation have been described. It may be post-translational modifications—glycosylation (for 5HT$_{2A}$ and 5HT$_{2C}$) or phosphorylation (for 5HT$_{2C}$), internalization (for 5HT$_{2A}$, 5HT$_{2B}$), as well as the ability to form homo- and heterodimers [27]. However, how these remarkable properties of the 5-HT$_2$ receptor affect their ability to influence body temperature of a warm-blooded organism is not yet clear.

Amino acid sequences of these three receptors have a fairly high degree of homology: from 45-50% in general [19] to 80% in transmembrane domains [27]. Therefore, it is not surprising that the synthesized ligands often have similar affinities to these three types of receptors, and the problem of their selectivity is still relevant [27]. Table 4 presents the results of studies devoted to 5-HT$_2$ receptors agonists and antagonists effects on body temperature in warm-blooded organisms. The results obtained in mice are separately given in the special table (Table 5), and they will be discussed separately.
Table 4. Effect of 5-HT\textsubscript{2A/C} agonists and antagonists on body temperature of warm-blooded animals.

| Compound | Dose and Route of Administration | Temperature Effect (Time of Its Achievement) | Object | Ambient Temperature Conditions | References |
|----------|---------------------------------|--------------------------------------------|--------|--------------------------------|------------|
| MK-212   | 0.03; 0.1; mg/kg i.p.           | no effect (30’)                           | Sprague-Dawley rats | 28–29.5 °C | [56]       |
|          | 1.0 mg/kg i.p.                 | 0.8 °C (15’)                             |        |                                |            |
|          |                                | 0.83 °C (30’)                            |        |                                |            |
|          | 3.0 mg/kg i.p.                 | 1.1 °C (30’)                             |        |                                |            |
| MK-212   | 1.25 mg/kg i.p.                | 0.5 °C (30’)                             |        |                                |            |
|          | 2.5 mg/kg i.p.                 | 0.75 °C (15’); 1.1 °C (30’); 1.1 °C (45’) |        |                                |            |
| mCPP     | 5 mg/kg i.p.                   | 0.75 °C (15’); 1.1 °C (30’); 1.2 °C (45’); 1.3 °C (60’); 1.3 °C (90’)] | Wistar rats | 25 °C | [158]  |
| mCPP     | 0.5 mg/kg oral                 | 0.48 °C (≈190’); 0.32 °C (≈57’)           | Health volunteers | | [159] |
| DOI      | 0.1 mg/kg i.p.                 | 0.4 °C (30’)                             | Sprague-Dawley rats | 29 °C | [160] |
| DOI      | 0.3 mg/kg i.p.                 | 1.3 °C (30’); 1.8 °C (30’)               |        |                                |            |
| DOI      | 1.0 mg/kg i.p.                 | 1.5 °C (30’)                             | Sprague-Dawley rats | 20 °C | [161]  |
| DOI      | 0.8 mg/kg i.v.                 | 0.9 °C (5’); 1.5 °C (10’); 2 °C (15’); 2.5 °C (20’); 3 °C (30’) Malignant hyperthermia | pigs    | | [162] |
| TFMPP    | 1 mg/kg i.p.                   | 0.7 °C (30’); 0.6 °C (60’)               |        |                                |            |
|          | 5 mg/kg i.p.                   | 0.9 °C (30’); 1.0 °C (60’); 0.9 °C (90’); 0.6 °C (120’); |        |                                |            |
|          | 10 mg/kg i.p.                  | 1.0 °C (30’); 1.3 °C (60’); 1.4 °C (90’); 1.1 °C (120’); |        |                                |            |
|          | 20 mg/kg i.p.                  | 0.8 °C (30’); 1.1 °C (60’); 1.3 °C (90’); 1.3 °C (120’); | Wistar rats | 28 °C | [163] |
| mCPP     | 1 mg/kg i.p.                   | 0.6 °C (60’); −0.5 °C (90’)              |        |                                |            |
|          | 5 mg/kg i.p.                   | 0.6 °C (60’); 0.9 °C (90’)               |        |                                |            |
|          | 10 mg/kg i.p.                  | 1.1 °C (30’); 1.2 °C (60’);              |        |                                |            |
|          |                                | 1.1 °C (90’); 0.9 °C (120’);             |        |                                |            |
|          | 20 mg/kg i.p.                  | 1.3 °C (30’); 1.3 °C (60’); 1.2 °C (90’); 1.2 °C (120’); |        |                                |            |
| DOI      | 1 mg/kg i.p.                   | 1.5 °C (60’)                             | Wistar rats | 21 °C | [164] |

References:
[56, 62, 158, 159, 160, 161, 162, 163, 164]
Table 4. Cont.

| Compound | Dose and Route of Administration | Temperature Effect (Time of Its Achievement) | Object | Ambient Temperature Conditions | References |
|----------|----------------------------------|---------------------------------------------|--------|---------------------------------|------------|
| DOI      | 2.5 mg/kg i.p.                   | 1.5 °C (60')                                | Wistar rats | 22 °C                           | [165]      |
|          |                                  | 0.6 °C (60')                                | Fawn-Hooded rats |                                |            |
| mCPP     | 2.5 mg/kg i.p.                   | 1 °C (30')                                  | Wistar rats | 21 °C                           | [166]      |
|          |                                  | 0.3 °C (30')                                | Fawn-Hooded rats |                                |            |
| mCPP     | 2.5 mg/kg i.p.                   | 1.2 °C (30')                                | Wistar rats |                                |            |
|          |                                  | 0.4 °C (60')                                | Fawn-Hooded rats |                                |            |
| DOI      | 1.25 mg/kg i.p.                  | 1.2 °C (30')                                | Wistar rats |                                |            |
|          |                                  | 0.5 °C (30')                                | no effect |                                |            |
| DOI      | 2.5 mg/kg i.p.                   | 2 °C (60')                                  | Wistar rats | [167]                           |            |
| mCPP     | 2.5 mg/kg i.p.                   | 1.2 °C (30')                                | Sprague-Dawley rats | room temperature | [69]      |
| DOI      | 1 mg/kg s.c.                     | 1.2 °C (30')                                | Wistar rats | 23 °C                           | [168]      |
| DOI      | Intrahypothalamic administration 0.2 µg | 1.38 °C (45') | Sprague-Dawley rats | room temperature | [71]      |
| DOI      | 0.025; 0.1 mg/kg s.c.            | no effect (20')                             | Sprague-Dawley rats | 21 °C                           | [169]      |
|          | 0.4; 1.6 mg/kg s.c.              | 1.0 °C (20')                                | Sprague-Dawley rats |                                |            |
| DOI      | 5 µg/kg i.v.                     | 0.25 °C (20'–60')                           | rabbits | 23–25 °C                        | [170]      |
|          | 50 µg/kg i.v.                    | 1.0 °C (40'–60')                            | Sprague-Dawley rats | 27 °C                           |            |
|          | 100 µg/kg i.v.                   | >2 °C (90'–120')                            | Sprague-Dawley rats |                                |            |
| DOI      | 100 µg/kg s.c.                   | 1.0 °C (90')                                | Sprague-Dawley rats | 27 °C                           |            |
| YM348    | 0.3 mg/kg per os                | 0.9 °C (60')                                | Zucker rats |                                |            |
|          | 1 mg/kg per os                  | 1.1 °C (60')                                | Sprague-Dawley rats | 25–28 °C                        | [171]      |
|          | 3 mg/kg per os                  | 1.3 °C (60')                                | Sprague-Dawley rats |                                |            |
| DOI      | 0.1 mg/kg s.c.                   | 1.4 °C (30')                                | Sprague-Dawley rats | 22 °C                           |            |
|          | 0.05 mg/kg s.c.                 | 0.29 °C ns                                  | Sprague-Dawley rats | 32 °C                           | [172]      |
| DOI      | 0.1 mg/kg s.c.                  | 0.64 °C (30'; 45'; 60')                     | Sprague-Dawley rats |                                |            |
|          | 0.5 mg/kg s.c.                  | 0.79 °C (15'; 30'; 45'; 60'; 90')           | Sprague-Dawley rats |                                |            |
| DOI      | 0.05 mg/kg s.c.                 | 0.5 °C ns                                   | Sprague-Dawley rats | 12 °C                           |            |
|          | 0.1 mg/kg s.c.                  | 0.5 °C (15'); 1.7 °C (75')                  | Sprague-Dawley rats |                                |            |
|          | 0.5 mg/kg s.c.                  | 1.2 °C (15'); 2.7 °C (75')                  | Sprague-Dawley rats |                                |            |
|          | 0.1 mg/kg s.c.                  | 0.1 °C ns                                   | Sprague-Dawley rats |                                |            |
|          | 0.1 mg/kg s.c.                  | 0.99 °C (30'; 45'; 60')                     | Sprague-Dawley rats |                                |            |
Table 4. Cont.

| Compound          | Dose and Route of Administration | Temperature Effect (Time of Its Achievement) | Object                  | Ambient Temperature Conditions | References |
|-------------------|---------------------------------|--------------------------------------------|-------------------------|-------------------------------|------------|
| 25B-NBOMe         | 0.25 mg/kg i.p.                 | no effect                                  | Sprague-Dawley rats     | 23 °C                         | [172]      |
|                   | 0.25 mg/kg i.p.                 | 0.8 °C (30′); 1 °C (60′); 1.2 °C (90′); 0.9 °C (120′) |                         | 29 °C                         |            |
| **Effect of 5-HT_{2A/C} antagonists** |                                |                                            |                         |                               |            |
| pirenpirone       | 0.01; 0.03; 0.1; 0.3 mg/kg i.p. | −0.15 °C (?s; −0.5 °C; −0.85 °C; −0.9 °C (<60′) | Sprague-Dawley rats     | 28–29.5 °C                     | [56]       |
| ketanserin        | 0.1; 0.3; 1; 3 mg/kg i.p.       | −0.2 °C (?s; −0.5 °C; −0.7 °C; −1.2 °C (<60′) |                         |                               |            |
| ritanserin        | 0.63 mg/kg i.p.                 | no effect                                  | Wistar rats             | 25 °C                         | [158]      |
|                   | 0.5; 1; 2 mg/kg i.p.            | no effect alone, but dose-dependently reduces hyperthermic effect of mCPP and TFMPP |                         |                               |            |
| ketanserin        | 0.6; 1.25; 2.5 mg/kg i.p        | −0.55 °C (90′)                             | Wistar rats             | 21 °C                         | [164]      |
| LY53857           | 1 mg/kg i.p.                    | no effect                                  |                         |                               |            |
| ketanserin        | 1 mg/kg i.p.                    | no effect                                  | Sprague-Dawley rats     | 21 °C                         | [168]      |
| ritanserin        | 1 mg/kg s.c.                    | no effect (30′)                            |                         |                               |            |
| amperozide        | 2 mg/kg s.c.                    | no effect (30′)                            |                         |                               |            |
| ketanserin        | 5 mg/kg i.p                     | no effect alone, but blocks DOI             | Sprague-Dawley rats     | 22 °C                         | [171]      |
|                   |                                 |                                            |                         | 32 °C                         |            |
| ketanserin        | 0.2 µg into preoptic anterior hypothalamus | 0.58 °C (180′) | 2 °C |                         |            |
|                   |                                 | 0.54 °C (180′)                             | 22 °C                   |                               |            |
|                   |                                 | 0.57 °C (180′)                             | 32 °C                   |                               |            |
| ketanserin        | 0.4 µg into preoptic anterior hypothalamus | 1.13 °C (180′) | 2 °C |                         | [173]      |
|                   |                                 | 1.0 °C (180′)*                            | 22 °C                   |                               |            |
|                   |                                 | 1.09 °C (180′)                            | 32 °C                   |                               |            |
|                   |                                 | 1.42 °C (180′)                            | 2 °C                    |                               |            |
|                   |                                 | 1.37 °C (180′)                            | 22 °C                   |                               |            |
|                   |                                 | 1.43 °C (180′)                            | 32 °C                   |                               |            |

Note: MK-112—2-chloro-6-piperazin-1-ylpyrazine; mCPP—1-(m-chlorophenyl)piperazine meta chlorophenyl piperazine; DOI—1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine; TFMPP—1-[3-(Trifluoromethyl)phenyl)piperazine]; YM348—(2S)-1-(7-ethylfuro[2,3-g]indazol-1-yl)propan-2-amine; 25B-NBOMe—2-(4-Bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine; LY38857—3-hydroxybutan-2-yl(2R,4R,7R)-6-methyl-11-(propan-2-yl)-6,11-diazetacryclo[7.6.1.0^{7,12,16}]hexadeca-1(16),9,12,14-tetraene-4-carboxylate; *—the value is taken from the text of the article, not from the table; ns—non significant; ?s—the authors did not indicate the significance.

One of the first studies of temperature effects of 5-HT, that focused specifically on the receptors of this neurotransmitter and where the “opposing roles of 5-HT_{2} and 5-HT_{1A} receptors” were really identified, was the work of Gudelsky et al. [56]. These authors, by using 5-HT_{1A} receptors agonist 8-OH-DPAT, 5-HT_{2} receptors agonist 2-chloro-6-piperazin-1-ylpyrazine (MK-212), and known antagonists of these receptors, proved that 5-HT_{2} receptors’ activation had the effect on rat body temperature as opposed to those caused by 5-HT_{1A} receptors activation: animals developed hyperthermia. The hyperthermic response to the activation of 5-HT_{2} receptors depended on the dose of administered agonist and decreased with the administration of antagonists. The maximal increase in body temperature in these experiments was approximately 1.1 °C.
Table 5. Effect of 5-HT\textsubscript{2A/C} agonists and antagonists on body temperature of mice.

| Compound       | Dose and route of Administration | Temperature Effect (Time of Its Achievement) | Object | Ambient Temperature Conditions | References |
|----------------|----------------------------------|---------------------------------------------|--------|---------------------------------|------------|
| **Effect of 5-HT\textsubscript{2A/C} agonists** |
| TFMPP, mCPP, MK-212 | 1 mg/kg s.c.                     | no effect alone (10'), but reduces the effect of 8-OH-DPAT | ICR    | 21 °C                           | [63]       |
| DOI, MK-212     | 0.1 mg/kg s.c.                   |                                             |        |                                 |            |
| DOI             | 0.5, 1.0, 2.5 mg/kg i.p.         | no effect (15', 30', 45', 60', 90', 120') | ICR    | 24 °C                           | [174]      |
| DOI             | 1 mg/kg i.p.; 5 mg/kg i.p.       | −1 °C (30', 45', 60', 90')                 | Ddy    | 24 °C                           | [175]      |
| DV-7028         | 10 mg/kg per os                  | no effect                                  |        |                                 |            |
| TCB-2           | 0.1; 0.5; 1.0; 2.5; mg/kg i.p.   | no effect (15', 30', 45')                  | C57Bl6J| plexiglass containers 20 °C     | [176]      |
| DOI             | 0.1; 0.5; 1.0; 2.5; 5.0 mg/kg i.p.| no effect (15', 30', 45')                  |        |                                 |            |
| DOI             | 1 mg/kg i.p.                     | no effect (each 5' over 24 h)              | C57Bl/L/6J| 22.5–23.5 °C                    | [177]      |
| 25CN-NBOH       | 1.5 mg/kg, s.c.                  | no effect                                  |        |                                 |            |
|                 |                                  | 1 °C (15')                                 | Mice Mix genetic background | Temperature of heat-pad = 37 °C | [178]      |

**Effect of 5-HT\textsubscript{2A/C} antagonists**

| Compound       | Dose and route of Administration | Temperature Effect (Time of Its Achievement) | Object | Ambient Temperature Conditions | References |
|----------------|----------------------------------|---------------------------------------------|--------|---------------------------------|------------|
| ritanserin     | 1 mg/kg per os; 10 mg/kg per os  | no effect                                   | Ddy    | 24 °C                           | [175]      |
| ketanserin     | 1 mg/kg per os                   | no effect                                   |        |                                 |            |
| MDL 11,939     | (1.0 mg/kg), i.p.                | no effect                                   | C57Bl6J|                                 | [176]      |
| ketanserin     | 1.0 mg/kg i.p. (180 μM)          | −2 °C                                       | CBA/Lac|                                 | [179]      |
|                 | 2.0 mg/kg i.p. (360 μM)          | −2.3 °C                                     |        |                                 |            |
|                 | 20 nM i.c.v.                     | −2.3 °C                                     |        |                                 |            |
|                 | 40 nM i.c.v.                     | −3.5 °C                                     |        |                                 |            |
| ketanserin     | 1 mg/kg i.p.                     | no effect (each 5' over 24 h)              | C57Bl/L/6J| 22.5–23.5 °C                    | [177]      |
|                 | 40 nmol i.c.v.                   | no effect (60')                             |        |                                 |            |
| ketanserin     | 1 mg/kg i.p.                     | no effect (60')                             | AKR/J  |                                 | [180]      |

Note: DV-7028—3-[2-[4-(4-Fluorobenzoyl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2H-pyrido[1,2-a]-1,3,5-triazine-2,4(3H)-dione hydrochloride; TCB-2—(4-Bromo-3,6-dimethoxybenzocyclobuten-1-yl)methylamine hydrobromide; 25CN-NBOH—N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine; MDL 11,939—α-Phenyl-1-(2-phenylethyl-4-piperidinemethanol; (*)—the authors did not indicate the exact time for the effect achievement.
Another important fact discovered by Gudelsky et al. [56] is the evidence that hyperthermia caused by 5-HT$_2$ receptors activation, as well as hypothermia in response to 5-HT$_{1A}$ receptors activation, is a phenomenon of central origin. The authors, using 5-HT receptor antagonist xylamidine, which did not penetrate the blood-brain barrier, showed that blockade of peripheral 5-HT receptors did not alter the hyperthermia induced by 5-HT$_2$ receptors activation.

A number of further studies on the effect of 5-HT$_2$ receptors agonists on body temperature in warm-blooded animals also confirmed their hyperthermic effect, the magnitude of which depended on the dose of the administered compound (Table 4).

It is difficult to say which subtypes of 5-HT$_2$ receptors are involved in this hyperthermic effect, especially if the affinities of the ligand for 5-HT$_{2A}$ and 5-HT$_{2C}$ are close. For example, pKi (a one of characteristic features of drug-receptor interaction) for DOI and the human 5-HT$_{2A}$ receptor is 7.4–9.2, for DOI and human 5-HT$_{2C}$ receptor pKi equals to 7.2–8.6 [89]. However, some authors, for example, Mazzola-Pomietto et al., argued that the increase in body temperature under the influence of DOI was the result of 5-HT$_{2A}$ receptors activation [164], and under the influence of mCPP it was the result of 5-HT$_{2C}$ receptors activation [166]. These authors substantiated their conclusions both by the influence of corresponding antagonists on the temperature effect, and by the emergence of behavioral reactions typical for the activation of the corresponding subtype of receptors in animals.

Zhang and Tao [171] raised the question of external temperature influence on the hyperthermic effect caused by 5-HT$_2$ receptors activation. They found that at higher ambient temperatures, the hyperthermic effect was more pronounced. The authors suggested the explanation being not only an undoubted decrease in heat loss with an increase in ambient temperature, but also an increase in 5-HT$_{2A}$ receptors affinity for DOI at elevated temperature. As an argument they cited the results of Dalpiaz et al. [181]. Latter authors, using the radioligand binding method, investigated the thermodynamic characteristics of three types of 5-HT receptors (5-HT$_{1A}$, 5-HT$_2$, 5-HT$_3$) in samples of anterior cortex of the rat brain at various temperatures—from 0 to 35 °C—and found that 5-HT$_2$ receptor affinity increased significantly with the rise of incubation temperature. Other receptors under study did not demonstrate similar dependency. However, it should be emphasized that Dalpiaz et al. [181] used $^3$H-ketanserin (antagonist) and unlabeled 5-HT (agonist) to characterize 5-HT$_2$ receptors. Later, it was found that 5-HT and ketanserin had different binding sites [19] and could not be used together in the investigations similar to those of Dalpiaz et al. [181]. In the experiments of Zhang and Tao [171], the compound began to act in animal organisms under the same temperature conditions (the initial body temperature of rats was the same). As a result of agonist action, body temperature of animals increased, but the maximal effect was 2.7 °C, so it is hardly worth talking about any thermodynamic changes in the affinity of the receptors. At the same time, the explanations based on the heat loss change under different temperature conditions are quite correct and physiological.

Gudelsky et al. [56] also carried out a targeted study of the effects of 5-HT$_2$ receptor antagonists on body temperature. The dose-dependent hypothermic effect that developed in response to the ketanserin or ritanserin administration highlighted the active role of 5-HT$_2$ receptors in body temperature maintenance in warm-blooded animals: not only activation of these receptors leads to a change in body temperature, but also their blockade. Changes in body temperature under activation or blockade of the receptors were of the opposite nature. Later, the hypothermic effect of 5-HT$_2$ receptors blockade was noted by Mazzola-Pomietto et al. [164] in rats, and Morishima and Shibano [175] and Naumenko et al. [179] in mice. Nevertheless in most studies, no shifts in body temperature in response to 5-HT$_2$ receptor antagonists administration were noted, although these substances reduced the hyperthermic response of agonists.
The results of Won and Lin [173] are somewhat apart from the others. These authors found the hyperthermic effect of ketanserin. This is not the only thing that surprises in this work. Researchers conducted experiments at different ambient temperatures using different doses of the drug. Surprisingly, a given dose of the drug produced the same temperature effect regardless of the ambient temperature. The authors explain this by different patterns of thermoregulatory responses at different temperature conditions. Sometimes it was $O_2$ consumption that changed in response to drug and ambient temperature, whereas in other cases it was skin temperature or evaporative heat loss, etc. Unexpectedly, the well-functioning thermoregulation system (its responses were documented) maintained the animal body temperature depending on the dose of drug administered regardless of the ambient temperature. It would be very interesting to identify the reasons for such an unexpected reaction.

5HT$_2$ receptor influence data on body temperature in mice (Table 5) serve as evidence for absence of hyperthermic effect of 5-HT$_2$ agonists in these animals, except the experiments of Buchborn et al. [178]. Moreover, the hypothermic effects of 5-HT$_2$ receptor agonists were also described [174,176]. However, the absence of recorded temperature effects of 5-HT$_2$ receptor agonists in mice is not the result of sensitivity lack of 5-HT$_2$ receptors to agonists in these animals: behavioral reactions developing in response to agonists of these receptors are perfectly clear and well defined. Obviously, the peculiarities of heat loss in mice can explain the results.

In mice, the ratio of body surface to its volume is greater than in other species listed in Table 4, and, accordingly, heat transfer is higher [91-93,95]. Body temperature is an integral indicator of the balance of heat production and heat loss. Attention should also be paid to the temperature conditions of the experiments. Thus, Buchborn et al. [178] conducted their studies on anesthetized animals placed on a heat-pad. The authors discovered the hyperthermic effect of the agonist when they raised the temperature of the heat-pad from 37 to 41 °C: after the injection of the agonist, body temperature of an animal rose by one degree compared to the injection of the solvent. The experiments of Fox et al. [176], in which the strongest (−4 °C) hypothermic effect of 5-HT$_2$ agonist was recorded, were carried out at 20 °C, that is lower than in other similar works. The authors also pointed out that the animals were placed in a plexiglass cylinder, and this could also significantly affect heat transfer. In this regard, it is useful to return to the classical study of Gudelsky et al. [56]. These researchers performed their study at 29 °C, when they worked with 5-HT$_2$ receptor agonist MK-212 and at 23 °C when they worked with 5-HT$_1A$ receptor agonist 8-OH-DPAT. This nuance gave them the possibility to emphasize the specificity of the receptors’ influences on body temperature in animals.

However the decrease in body temperature by 4 °C observed by Fox et al. [176] is a value too large to be explained simply by the effects of heat loss, especially since it was observed only at the highest dose of the drug. Perhaps this dose caused some behavioral effects that the investigators did not record, but which could significantly affect the heat loss. The fact that hypothermia was prevented by the administration of an antagonist can be explained by the action of an antagonist on behavioral reactions: the pretreatment with selective 5-HT$_2A$ antagonist MDL 11,939 (used in experiments of Fox et al. [176]) prevented these behavioral effects, and together with them the hypothermic effect of a high dose of TCB-2. Another explanation of hypothermia induced by high dose of TCB-2 appears to be the effect of this compound (in such dose) on peripheral 5-HT$_2A$ receptors. Sugimoto et al. [182] i.p. treated ICR mice with various doses of 5-HT and observed a pronounced hypothermic effect comparable to those described by Fox et al. [176]. By administering various 5-HT receptor antagonists, the authors have shown that this effect is mediated by peripheral 5-HT$_2$ receptors [182].

Both an increase in heat production and a decrease in heat loss from body surface (Table 6) lead to hyperthermia after 5-HT$_2$ receptors’ activation. An increase in total metabolism, assessed by $O_2$ consumption, in response to intrahypothalamic administration of DOI in rats was firstly noted by Lin et al. [71]. In Zucker rats, Hayashi et al. [170]
also observed an increase in total metabolism measured by O$_2$ consumption and CO$_2$ excretion after 5-HT$_{2C}$ receptors’ activation. As for the source of heat production, to date, only the participation of BAT in these processes after 5-HT$_2$ receptors activation has been experimentally proven. Ootsuka and Blessing [101] showed this by measuring the temperature of BAT after s.c. administration of DOI, Nakamura et al. [172]—after i.p. injection of 25B-NBOMe.

Table 6. Effect of 5-HT$_2$ receptor activation by their selective agonists on thermoregulatory responses in warm-blooded organisms.

| Change in Thermoregulatory Response | Change in Registered Parameter | Ambient Temperature Conditions | Object | Ligand (Dose and Route of Administration) | Reference |
|------------------------------------|--------------------------------|--------------------------------|--------|------------------------------------------|-----------|
| ↑General metabolism                | ↑O$_2$ consumption            | Room temperature              | Sprague-Dawley rat | DOI (0.2 µg into the hypothalamus) | [71]       |
|                                   | ↑O$_2$ consumption; CO$_2$ excretion |                          | Zucker fa/fa rats     | YM348 (0.3; 1; 3 mg/kg per os) | [170]     |
| ↑Heat production                   | ↑BAT temperature               | 25–28 °C                      | Sprague-Dawley rat | DOI (0.1 mg/kg s.c) | [101]     |
|                                   | ↑BAT temperature               | 29 °C                         | Sprague-Dawley rat | 25B-NBOMe (0.25 mg/kg i.p.) | [172]     |
| ↓Heat loss                         | ↓skin temperature              | Room temperature              | Sprague-Dawley rat | DOI (0.2 µg into the hypothalamus) | [71]       |
|                                   | ↓peripheral blood flow 23–25 °C | Rabbits                      | DOI (5; 50; 100 µg/kg, i.v.) | [169]     |
|                                   |                               | Sprague-Dawley rat | DOI (100 µg/kg s.c.) | [169]     |
|                                   | ↓peripheral blood flow 25–28 °C | Sprague-Dawley rat | DOI (0.1 mg/kg s.c) | [101]     |
|                                   | ↓skin temperature              | Sprague-Dawley rat | 25B-NBOMe (0.25 mg/kg i.p.) | [172]     |

Notes: ↓—decrease of parameter; ↑—increase of parameter.

A decrease in heat loss from body surface after 5-HT$_2$ receptors activation was reported by Lin et al. [71], who noted a decrease in paw skin temperature in rats. This conclusion was also confirmed by Nakamura et al. [172], who observed a decrease in tail skin temperature in animals under the same treatment. An irrefutable argument in favor of this conclusion is provided by the experiments of Blessing et al. [101,169,183], in which the authors directly measured peripheral blood flow and in which its decrease after 5-HT$_2$ receptor activation was recorded.

An important finding of Blessing and Seaman [169] is the evidence that the decrease in peripheral blood flow following 5-HT$_2$ receptors activation is mediated by the sympathetic nervous system. In their experiments, after unilateral sectioning of the cervical sympathetic trunk, the ipsilateral ear pinna decrease in blood flow in response to DOI was abolished or substantially reduced. So, as the authors emphasize, “vasoconstricting effect of DOI is mediated by a CNS action of the drug, not by a direct action on peripheral vessels” [169].

A different point of view on the origin of hyperthermia caused by 5-HT$_2$ receptors activation is shared by Nakamura et al. [172]. As indicated earlier, after 5-HT$_2$ receptor agonist 25B-NBOMe administration, they observed a hyperthermic reaction accompanied by peripheral vasoconstriction and an increase in BAT temperature. However, 5-HT$_2$ receptor antagonist sarpogrelate administration significantly reduced the severity of vasoconstriction and prevented the development of hyperthermia. On the basis of these results, the authors concluded that peripheral 5-HT receptors significantly con-
tributed to the observed response. Nakamura et al. [172] used sarpogrelate, suggesting that it does not cross the blood-brain barrier. However, there are different opinions on this in literature [184–186]. As for an increase in BAT thermogenesis, the authors associate this phenomenon with the influence of peripheral 5-HT. According to the views of Crane et al. [187] and Hansson et al. [188], 5-HT receptors are present on adipocytes and some of them (including 5-HT$_2$) suppress lipolysis. Nakamura et al. [172] tested the hypothesis about the effect of peripheral 5-HT on BAT thermogenesis. At temperature of 29 $^\circ$C (the temperature at which hyperthermia developed in the experiments of these authors), the blood level of 5-HT in experimental animals has been lowered. Investigators elevated it by i.p. injection of the mediator. Enhanced level of 5-HT indeed reduced the time during which the temperature of BAT was high. Thus, this study of Nakamura et al. [172], as well as the above-mentioned investigation of Sugimoto et al. [182], draw attention to 5-HT$_2$A receptors in the peripheral organs, which can also affect the processes of heat production and heat loss.

Ootsuka et al. [183] tried to find out the CNS location of 5-HT$_2$ receptors that affect the activity of sympathetic nerves. Electrical stimulation of neurons in the raphe/parapiramidal region resulted in increased sympathetic nerve discharges and decreased peripheral blood flow measured in rabbits on the ear and in rats on the tail. 5-HT$_2$ receptor antagonist ((trans-4-((3Z)3-(2-Dimethylaminoethyl)oxyimino)-3-(2-fluorophenyl)-propen-1-yl)-phenol, hemifumarate (SR 46349B, 0.1 mg/kg, i.v.)) administration significantly reduced the degree of vasoconstriction in animals caused by electrical stimulation, confirming the presence of 5-HT$_2$A receptors in this region. Moreover, in this and in subsequent work [188], the investigators have shown the existence of spinal 5-HT$_2$A receptors that contribute to sympathetically induced cutaneous vasoconstriction regulated by raphe/parapyramidal neurons in brainstem.

Thus, it has been shown that pharmacological activation and blockade of 5-HT$_2$A receptors can cause opposite changes in body temperature in a warm-blooded organism. However, the question always arises whether these mechanisms work in any physiological models. The answer to this question is positive, at least for stress-induced hyperthermia. Ootsuka et al. [189] showed that an increase in BAT temperature in rats under restraint stress can be attenuated by selective blockade of 5-HT$_2$A receptors. Beig et al. [190] and Sinh and Ootsuka [191] also blocked hyperthermia in social stress models by 5-HT$_2$A receptor antagonist.

The involvement of 5-HT$_2$A receptors in thermoregulatory reactions in vivo has been shown [126] in the model of long-term adaptation to cold [127]. The description of the model and the rationale for its use for this purpose were given earlier. 5-HT$_2$A receptors gene expression was studied in cold-adapted and control animals in frontal cortex, hypothalamus, hippocampus, and midbrain regions. The adaptation resulted in an increase in the 5-HT$_2$A receptor mRNA level in hypothalamus and its decrease in frontal cortex. In light of the above-mentioned pharmacological data that 5-HT$_2$A receptors activation contributes to an increase in heat production and a decrease in heat loss, an elevation in the mRNA level of 5-HT$_2$A receptors in hypothalamus in animals adapted to cold is perceived as a quite expedient phenomenon, since under the influence of these receptors, the mechanisms leading to improved protection from cold are activated. It should be emphasized that the detected changes turned out to be specific for hypothalamus, which is obviously associated with its role as a center of thermoregulation. In hippocampus and midbrain, cold adaptation did not change 5-HT$_2$A receptor mRNA expression, while in cortex it led to changes opposite to those observed in hypothalamus: the amount of mRNA of this receptor in cortex significantly decreased. It is difficult to say to what particular physiological processes a decrease in 5-HT$_2$A receptor gene expression in cortex may be related, but it is interesting to note that the opposite changes—an increased number of serotonin 5-HT$_2$ receptors in frontal cortex—were observed in rats specially selected for increased ability to the development of hypothermia in response to 8-OH-DPAT administration [45]. A decrease in the number of 5-HT$_2$ receptor binding sites in cortex was also noted after chronic activation of these
receptors [192] by their agonist. 5-HT2 activation under exposure to cold seems reasonable, and under prolonged exposure to cold (cold adaptation), 5-HT2 activation appears to be chronic. So, a decrease in the 5-HT2A mRNA level in cortex found in these experiments is quite consistent with the results of Buckholtz et al., [192]. However, the physiological meaning of changes in 5-HT2 receptors in this brain region as a result of chronic cold impact is not yet clear.

In addition to the evidence listed above for the involvement of 5-HT2 receptors in thermoregulation, these receptors have many functions that are also associated with maintaining the temperature balance of the whole organism, but they have not yet been studied in this vein. First of all, it is the effect of these receptors on eating behavior. Changes in eating behavior after activation or inhibition of receptors are investigated as an independent behavioral response. However, there is no information regarding correlations between eating behavior and the temperature balance of the body under influence of 5-HT receptors. 5-HT2B receptors exert the greatest influence on eating behavior, all other 5-HT receptors in comparison with them in this respect “act downstream”, as the authors of the last review figuratively put [27].

Another important aspect of the 5-HT2 receptors action is their involvement in the regulation of carbohydrate and fat metabolism [26,27,146,150,185,187,193–198]. 5-HT2 receptors, along with many other 5-HT receptors, are expressed in both white and brown adipose tissue, take part in the differentiation of adipocytes, and influence lipolysis and lipogenesis.

For some tissues, the 5-HT2 receptors’ effect on mitochondria, the “energy stations of cells”, has been shown. For example, in mice with a knockout of the 5-HT2B receptor gene, both morphological changes in the mitochondria of cardiomyocytes and changes in the functioning of a number of mitochondrial enzymes were found [199]. Harmon et al. [200] showed the effect of 5-HT2A and 5-HT2C receptors on mitochondrial biogenesis—“an intricate process that drives coordinated transcription of both mitochondrial DNA and nuclear-encoded genes to increase cellular mitochondrial content” in the kidney. Nonogaki et al. [157] described changes in gene expression for uncoupling proteins (UCPs), important mitochondrial proteins [201], in white and brown adipose tissues, as well as in muscle and liver, in 5-HT2C knockout mice.

Thus, a large amount of experimental material indicating the involvement of 5-HT2 receptors in the processes of heat production and heat loss, as well as their participation in a number of intracellular metabolic processes has been accumulated. It would be very desirable to receive experimental evidence of how intracellular processes activated (or inhibited) by 5-HT2 receptors affect the functioning of the organism as a whole. Such a combination of molecular and organismic levels of research would undoubtedly be very useful for all branches of biological science.

3. 5-HT3 Receptor

5-HT3 receptors are the only ones among numerous 5-HT receptors that are ion channels [19,26,27,202,203]. A brief history of their research can be found in a mini-review of Lummis [203]. This receptor is a membrane structure of five symmetrically located subunits surrounding the ion-conducting pore. Each subunit has N- and C-terminals located outside the cell, four transmembrane domains, and an intracellular loop between third and fourth transmembrane domains. The extracellular terminals are responsible for ligand binding and, therefore, are the sites of action for agonists and antagonists. The second transmembrane domain is involved in the formation of the canal pore, and its sites, together with some sites of the intracellular loop, control the movement of ions across the cell membrane [204–207].
The subunits that form the 5-HT\textsubscript{3} receptor are not always uniform. To this date, in humans, for example, five different subunits have been found (5-HT\textsubscript{3A}-5-HT\textsubscript{3E}). Subunits are proteins that are structurally similar, formed not as a result of alternative splicing, but as a result of the expression of the corresponding genes. In humans, the genes for subunits A and B of the 5-HT\textsubscript{3} receptor are located in the 11th chromosome, C, D, E—in the third [32]. In addition to this abundance of subunits, their splicing variants and various mutations affecting the ion permeability of this channel have also been described [27,207–209]. The leading role in 5-HT\textsubscript{3} receptor formation, apparently, belongs to a subunit A. Thus, a functioning homomeric 5-HT\textsubscript{3} receptor can be obtained only by combining these subunits, and for the functioning of a receptor “assembled” from various subunits, at least one must be A. However, the most common are believed to be ion channels consisting of A and B subunits [27,207,210–212]. The features of heteromeric 5-HT\textsubscript{3} receptors formation apparently are tissue-specific [203,210]. The pharmacological properties of the homo- and heteromeric 5-HT\textsubscript{3} receptor can differ significantly [210,212].

For 5-HT\textsubscript{3} receptor subunits, chaperone proteins have been described. They are likely to promote correct folding, oligomerisation, post-translational modification, and/or export from endoplasmic reticulum [213]. Glycosylation is suggested as a post-translational modification of 5-HT\textsubscript{3} receptor subunits: sites for this have been found on both A and B subunits [214].

The 5-HT\textsubscript{3} receptors are localized both in the CNS and in the periphery. In the CNS, they are expressed in many areas [215,216]. However the highest levels of this receptor were mapped within the dorsal vagal complex (nucleus tractus solitarius, area postrema, and dorsal motor nucleus of the vagus nerve). Relative to the dorsal vagal complex 5-HT\textsubscript{3} receptor expression in forebrain is low [22,216]. At the periphery, the 5-HT\textsubscript{3} receptor was found in a wide range of tissues, including gastrointestinal tract, immune cells, heart, blood vessels, skin, adipocytes [196,207,211].

At the cellular level, activating the 5-HT\textsubscript{3} receptor regulates the Ca\textsuperscript{2+}, Na\textsuperscript{+}, and K\textsuperscript{+} ions flow, that leads to the change of membrane potential and evidences the involvement of this receptor in the mechanisms of signal transduction [202,207,215,217]. At the organism level there are data concerning the participation of 5-HT\textsubscript{3} receptors in the function of gastrointestinal tract, in modulation of pain, alcohol dependence, and some affective disorder [211].

“However, almost 50 years after the identification of the 5-HT\textsubscript{3} receptor, we are now at the threshold of discovering the physiological role of 5-HT\textsubscript{3} receptors in the CNS” (Pascal Chameau and Johannes A. van Hooft, [217]). One poorly researched physiological roles of the 5-HT\textsubscript{3} receptor is its participation in the regulation of body temperature.

There are only a few studies related to this problem (Table 7). Mazzola-Pomietto et al. [218] were among the first to investigate the effect of activation of serotonin 5-HT\textsubscript{3} receptors on body temperature. They found a hyperthermic (slightly more than + 0.5 °C) effect of m-chlorophenylbiguanide (mCPBG) 5-HT\textsubscript{3} receptor agonist after its i.p. administration on rats. Blockade of 5-HT\textsubscript{3} receptors (i.p. administration of antagonists bemesetron—MDL72222—or ondansetron) did not affect the body temperature of animals, although MDL72222 reduced the hyperthermic effect of mCPBG. Ondansetron did not influence the hyperthermic effect of mCPBG. The authors could not give a clear answer to the question why blockade of receptors by different antagonists has different effects on the hyperthermic response caused by receptor activation, and reasonably concluded that additional studies of temperature effects of 5-HT\textsubscript{3} receptors are required.
Table 7. Effect of 5-HT₃ agonists and antagonists on body temperature in warm-blooded animals.

| Compound     | Dose (Route of Administration) | Maximal Effect (°C) | Time of Its Achievements | Object                        | References |
|--------------|---------------------------------|---------------------|--------------------------|-------------------------------|------------|
| mCPBG        | 0.1 mg/kg (i.p.)                | no effect           |                          |                               |            |
|              | 1 mg/kg (i.p.)                  | 0.5                 | ≈30'                     | Wistar rats                   | [218]      |
|              | 10 mg/kg (i.p.)                 | 0.6                 | ≈30'                     |                               |            |
| MDL72222     | 0.1; 1; 10 mg/kg (i.p.)         | no effect           |                          |                               |            |
| ondansetron  | 0.1; 1 mg/kg(i.p.)              | no effect           |                          |                               |            |
| 2-Me-5-HT    | 5 µg (i.c.v.)                   | ≈−0.62              | 45'                      | Sprague-Dawley rats           | [219]      |
|              | 10 µg (i.c.v.)                  | −1.1                | 45'                      |                               |            |
|              | 20 µg (i.c.v.)                  | −1.5                | 45'                      |                               |            |
|              | 1–5 mg/kg (i.p.)                | no effect           | During 2 h                |                               |            |
| ondansetron  | 5, 10, 20 µg (i.c.v.)           | no effect           |                          |                               |            |
|              | 50, 100, 300 mg/kg (i.p.)       | no effect           | During 150'               |                               |            |
| tropisetron  | 50, 100, 300 mg/kg (i.p.)       | no effect           |                          |                               |            |
|              | 5, 10, 20 µg (i.c.v.)           | no effect           |                          |                               |            |
| 2-Me-5-HT    | 4 mg/kg (i.p.)                  | no effect           | During 6 h                | Sprague-Dawley rats           | [220]      |
| mCPBG        | 160 nmol (i.c.v.)               | −4                  | 30'                      | AKR/J mice                    | [79]       |
|              | 80 nmol (i.c.v.)                | −2                  |                          |                               |            |
|              | 40 nmol (i.c.v.)                | −2                  |                          |                               |            |
|              | 20 nmol (i.c.v.)                | no effect           |                          |                               |            |
|              | 0.5; 1; 5; 10 mg/kg (i.p.)      | no effect           |                          |                               |            |
| mCPBG        | 40 nmol (i.c.v.)                | −2.3                | 30'                      | CBA/Lac mice                  | [80]       |
|              |                                 | −5                  |                          | C57Bl/6 mice                  |            |
|              |                                 | −2.6                |                          | AKR/J mice                    |            |
|              |                                 | −5.1                |                          | C57Bl/6 mice                  |            |
|              |                                 | −3.1                |                          | BALB/c mice                   |            |
|              |                                 | −3.2                |                          | ICR mice                      |            |
| mCPBG        | 40 nmol (i.c.v.)                | −5                  | 30'                      | C57Bl/6 mice                  | [30]       |
|              |                                 | −5                  |                          | C57Bl/6 mice                  |            |
|              |                                 | −4                  |                          | DBA mice                      |            |
|              |                                 | −5.9                |                          | Asn mice                      |            |
|              |                                 | −3                  |                          | BALB mice                     |            |
|              |                                 | −5.1                |                          | CBA mice                      |            |
|              |                                 | −3.2                |                          | ICR mice                      |            |
|              |                                 | −2.5                |                          | AKR mice                      |            |

Note: mCPBG—m-chlorophenylbiguanide; MDL72222—bemesetron; 2-Me-5-HT—2-methyl-5-hydroxytryptamine maleate.
In the studies of Kandasamy [219], a huge difference was found between the effects of i.p. and i.c.v. administration of 5-HT\textsubscript{3} receptor agonist 2-methyl-5-hydroxytryptamine maleate (2-Me-5-HT). For 45 min, the centrally administered agonist dose-dependently reduced the animal’s temperature, which then remained at this level for more than 2 h. I.p. administration of the drug had no effect. 5-HT\textsubscript{3} receptor antagonists—ondansetron and tropisetron—regardless of the administration route, did not affect body temperature of an animal in the state of normothermia. In hypothermic animals, these antagonists acted differently depending on the type of hypothermia. Kandasamy [219] investigated 2 types of hypothermia: (1) caused by central 5-HT\textsubscript{3} receptors activation by their agonist 2-Me-5-HT and (2) caused by gamma irradiation of an animal. Tropisetron, regardless of the administration route, dose-dependently reduced the severity of hypothermia in both models. Ondansetron, administered both i.p. and i.c.v., also dose-dependently reduced gamma-irradiation-induced hypothermia, but had no effect on central 5-HT\textsubscript{3} receptor-induced hypothermia. What the difference between these models of hypothermia from the point of view of the processes of heat production and heat loss is, and why the actions of 5-HT\textsubscript{3} receptor antagonists in these models are different is not yet clear.

The ability of ondansetron (0.5 mg/kg i.p.) to reduce hypothermia has been reported by Ngampramuan et al. [221]. In their experiments, hypothermia was associated with motion sickness induced by rotating rats in their individual cages in the horizontal plane.

Experiments by Martin et al. [220] confirmed the results of Kandasamy [219] that there was no effect on animal body temperature by 5-HT\textsubscript{3} receptor agonist 2-Me-5-HT administered i.p. Testing the hypothesis about the possible effect of blockade of 5-HT\textsubscript{3} receptors (ondansetron, 0.1 mg/kg i.p.) on body temperature of an animal in a state of LPS-induced hyperthermia (LPS 50 µg/kg i.p.) did not reveal such an effect. Time-courses of body temperatures in LPS-treated animals with pretreatment by ondansetron or vehicle were the same.

Another attempt to identify the possible effect of 5-HT\textsubscript{3} receptors on body temperature was made by Naumenko et al. [79]. Such authors like Mazzola-Pomietto et al. [218] worked with 5-HT\textsubscript{3} receptors agonist mCPBG, but, unlike their predecessors, tested the effect of the drug both with peripheral (i.p.) and central (i.c.v.) administration. A powerful hypothetic effect of the i.c.v.-administered drug was found. The effect both in the magnitude of the drop in body temperature and in the duration clearly depended on the dose: mCPBG (160 nmol, i.c.v.) reduced the body temperature of an animal by almost 4 °C and hypothermia lasted up to 7 h, the effect of 40 nmol mCPBG (i.c.v.) was about −2 °C and lasted about 3 h. Central administration of 5-HT\textsubscript{3} receptor antagonist ondansetron reduced the severity of hypothermia. Peripheral administration of mCPBG had no effect on body temperature, even at high doses. Based on this, the authors made a logical conclusion that mCPBG did not penetrate the blood–brain barrier. The authors tested their conclusion that brain 5-HT\textsubscript{3} receptors activation leads to hypothermia on mice of six inbred strains. Hypothermia induced by brain 5-HT\textsubscript{3} receptor activation developed in animals of all investigated strains. The temperature decrease (after 40nM mCPBG i.c.v.) ranged from −2.6 °C in AKR/J mice to −5.5 °C in CBA/Lac mice. Later, this conclusion was confirmed on mice of eight inbred strains [30]. Comparing the discovered hypothetic effect of brain 5-HT\textsubscript{3} receptor activation with the known effect of 5-HT\textsubscript{1A} receptor activation, the authors emphasize its depth and duration [79]: a drop in body temperature after 5-HT\textsubscript{1A} activation is usually about 1.5 °C (Table 1), with the exception of rare cases of hypersensitivity to an agonist for these receptors, and lasts no more than one and a half hours. At the same time, hypothermia caused by 5-HT\textsubscript{3} receptor stimulation was more than −2.5 °C and its duration was up to 6–7 h.

The discovery of such a powerful effect of central 5-HT\textsubscript{3} receptors activation on animal body temperature has raised the question about its thermoregulatory mechanisms. As it was revealed [80], activation of central 5-HT\textsubscript{3} receptors decreases heat production (O\textsubscript{2} consumption and CO\textsubscript{2} expiration) and increases heat loss (to estimate this parameter, the temperature of the tail skin was measured). In addition, it was found that the metabolism
switched to a more economical work mode. This conclusion was made based on the analysis of the respiratory exchange ratio (RER). The RER in m-CPBG-treated animals decreased during the first 15 min after injection and then became stable. RER decrease takes place during exposure to cold [222,223] and starvation [222]. This is important because lipids are the metabolic substrates that provide more economical consumption of energy resource per unit of calories supplied when these substrates are oxidized. Thus, the m-CPBG influence on metabolic processes consists not only in a decrease in total metabolism, but also in switching the metabolism to a more economical type of energy consumption [80].

Knockout of the 5-HT$_3$ receptor gene leads to significant metabolic changes: in mice with this mutation (Htr3a KO), O$_2$ consumption increases and fat metabolism is altered—they are resistant to obesity induced by high fat diet [196]. The fact that O$_2$ consumption in Htr3a KO mice increases coincides with the data on a decrease in O$_2$ consumption after 5-HT$_3$ receptors' activation [80].

Thus, all available data indicate that central 5-HT$_3$ receptors activation leads to a decrease in body temperature of a warm-blooded organism [30,79,219], and this occurs due to a decrease in heat production and an increase in heat loss [80]. Data on 5-HT$_3$ receptor blockade are ambiguous. As for peripheral 5-HT$_3$ receptors, according to a large number of studies [79,219,220], theirs activation has no effect on body temperature. The results of Mazzola-Pomietto et al. [218] contradict the others. It can, of course, be assumed that there are interstrain differences between Wistar rats (the object of the study by Mazzola-Pomietto et al. [218]) and Sprague-Dawley ones (the object of the study by Kandasamy, as well as Martin et al. [219,220]). Without any doubt, this assumption requires experimental verification. The fact that the peripheral 5-HT$_3$ receptor does not affect body temperature is also evidenced by the results of Sugimoto et al. [182]. These authors investigated the effects of peripherally administered 5-HT on rectal temperature and observed dose-dependent hypothermia in experimental animals. 5-HT$_3$ receptor antagonist tropisetron did not attenuate this effect.

5-HT$_3$ receptors of adipocytes are also the peripheral 5-HT$_3$ receptors and their role in metabolic processes of these cells is investigated intensively [196]. Working with a culture of immortalized brown adipocytes (IBA), Oh et al. [196] found that activation (by mCPBG) and blockade (by ondansetron) of the 5-HT$_3$ receptor cause opposite changes in adipocytes functioning (experiments were performed at the background of the β-3 adrenoreceptor stimulation, without stimulation of β-3 adrenoreceptors 5-HT$_3$ receptor effects were absent). Ondansetron increased mRNA expression of thermogenic genes, such as Ucp1 in IBA. Conversely, m-CPBG decreased the Ucp1 mRNA level in IBA. O$_2$ consumption of the BAT increased as a result of 5-HT$_3$ receptor blocking. Ex vivo experiment using primary BAT from Htr3a KO mice showed similar results. Thermogenic gene expressions, including Ucp1 expression, were higher in BAT of Htr3a KO mice. Moreover mitochondrial biogenesis increased in BAT of Htr3a KO mice. Thus, studies by Oh et al. [196] revealed an inhibitory effect of the 5-HT$_3$ receptor on BAT thermogenesis. However it is still not clear what the proportion of thermogenesis induced (suppressed) by the blockade (activation) of the adipocytes 5-HT$_3$ receptor in the total heat production of the body is.

Information about the influence of the 5-HT$_3$ receptor on the other source of heat in an organism—on shivering thermogenesis—can be partly found in clinical investigations. As usual, the authors study the influence of 5-HT$_3$ receptor antagonists on post-operative shivering (POS). The conclusions of meta-analysis of such data are almost the same year by year. “... More high-quality randomized controlled trials with larger sample size are still required to draw a definite conclusion about the preventive efficacy of 5-HT$_3$ receptor antagonists on POS prevention in the future” [224]; “... The perioperative administration of 5-HT$_3$ receptor antagonists may be an effective measure for the prevention of POS in patients undergoing spinal anesthesia. However, further studies investigating different types of surgeries are required” [225]. In general, these investigations evidence that 5-HT$_3$ receptors influence shivering thermogenesis, but the quantification of this influence is still
required. The data about the role of these receptors in the processes of body temperature regulation in natural conditions would be very desirable.

4. 5-HT$_7$ Receptor

The 5-HT$_7$ receptor was the last 5-HT receptor to be discovered. The feature of its discovery lies in the fact that it was not discovered as a target for a new pharmacological compound. It was identified from the screening of cDNA libraries by several independent research groups in 1993 [226–229]. The 5-HT$_7$ receptor belongs to the super-family of GPCRs, is metabotropic, and as all 5-HT metabotropic receptors consists of seven transmembrane domains and extracellular N- and intracellular C-terminals. In transmembrane domains, its homology with 5-HT$_1$ receptors is close to 50%, with 5-HT$_2$ receptors—close to 40%. As of today, 5-HT$_7$ receptor genes are identified not only for human and most usual laboratory models—rats and mice, but also for many other species. The human 5-HT$_7$ receptor gene (HTR7) is located on chromosome 10, mice Htr7—on chromosome 19. HTR7 consists of four exons and codes a protein of 479 amino acids, rodent (mice, rats) Htr7 consists of three exons and codes a protein of 448 amino acids [32]. For the 5-HT$_7$ receptor, splicing variants are shown, but they do not exhibit major differences in their functional properties [27], except for the differential pattern of internalization displayed by the human 5-HT$_7$ receptor (d) isoform [230,231]. Tissue–specific splicing differences between spleen and brain were found in humans [232]. The existence of the 5-HT$_7$ receptor pseudogene has also been reported [27]. However, it is described for human and rhesus monkeys, not for rats or mice [233,234].

The 5-HT$_7$ receptor can undergo post-translational modifications such as N-glycosylation and palmitoylation. However, if the functional significance of N-glycosylation has not yet been clarified, palmitoylation is important for switching intracellular signal transduction [27,38,230,231,235–237].

Signal transduction by the 5-HT$_7$ receptor realizes through different pathways. This receptor is positively coupled to adenylate cyclase through stimulatory Gs proteins, and its activation results in an increase in cAMP. In addition, it interacts with G$_{12}$ protein and has also “non-canonical” signaling pathways: ERK and small G-proteins [26,27]. It has been recently demonstrated that these receptors may form homo- and hetero-dimers (with the 5-HT$_{1A}$ receptor). However, dimerization does not affect 5-HT$_7$ receptor mediated signaling [27,236,238].

The presence of 5-HT$_7$ receptors was shown in both the periphery tissues and in the CNS of various species by a wide variety of techniques. The CNS 5-HT$_7$ receptors were found in the cortex, hypothalamus, thalamus, hippocampus, and also the spinal cord. 5-HT$_7$ receptors are involved in the processes of memory and learning, modulation of circadian rhythms, sleep, pain perception, and others [27,37,230,231,234,235,237]. Participation in body temperature regulation is one of 5-HT$_7$ receptors functions too.

The discovery of 5-HT$_7$ receptor’s ability to influence body temperature, as the discovery of the receptor itself, was not traditional. Usually, the investigator begins the study of the receptor role in body temperature regulation from regarding the temperature changes induced by high selective agonists for this receptor. Exactly in this way, the influence of 5-HT$_1$$_A$, 5-HT$_2$, and 5-HT$_3$ receptors on body temperature of experimental animals was found. As for the 5-HT$_7$ receptor, the investigation of its role in maintaining body temperature began from the selective antagonist that attenuated the reduction in body temperature induced by other pharmacological compounds. Hagan et al. [239] were the first to establish the association between the 5-HT$_7$ receptor and 5-HT-induced hypothermia. They demonstrated that 3-[(2R)-2-[(4-methylpiperidin-1-yl)ethyl]pyrrolidin-1-sulfonyl]phenol (SB-269970), a high-selective antagonist for the 5-HT$_7$ receptor, attenuated the reduction in body temperature induced by nonselective 5-HT receptor agonist 5-carboxamidotryptamine (5-CT) in guinea pigs. Later, the ability of 5-HT$_7$ receptor antagonist to attenuate hypothermic effect of 5-CT was confirmed by other investigators [240,241]. In parallel, evidence of 5-HT$_7$ receptor effect on body temperature was obtained in mice with a knockout of the gene for
this receptor [75,241,242]. Mice lacking the Htr7 gene (Htr7KO), in contrast to WT animals, did not lower their body temperature in response to 5-HT administration [242], low doses of 5-CT [241,242], as well as low-dose of 8-OH-DPAT [75] (Table 8).

Table 8. Changes in body temperature of mice lacking the Htr7 gene (Htr7 KO) and control (WT) ones after intraperitoneal injection of compounds inducing hypothermia.

| Hypothermia-Inducing Compound | Dosa (mg/kg) | ΔT Body (Time of Effect) | Object | Reference |
|------------------------------|-------------|--------------------------|--------|----------|
| 5-HT                         | 5           | −3.1 °C (30′)            | WT     |          |
|                              |             | −2 °C (60′)              |        |          |
|                              |             | no change                | Htr7 KO| [242]    |
| 5-CT                         | 0.5         | −2 °C (30′)              | WT     |          |
|                              | 3           | −4.5 °C (120′)           |        |          |
|                              | 0.5         | no change                | Htr7 KO|          |
|                              | 3           | −1.2 °C (120′)           |        |          |
| 5-CT                         | 0.1         | −1.2 °C ns               | WT     | [241]    |
|                              | 0.3         | −2.8 °C                  |        |          |
|                              | 1           | −3.9 °C                  |        |          |
|                              | 0.1; 0.3; 1 | no change                | Htr7 KO| *        |
| 8-OH-DPAT                    | 0.3         | −0.7 °C (30′)            | WT     | [75]     |
|                              | 0.6         | −1.2 °C (30′)            |        |          |
|                              | 1           | −1.5 °C (30′)            |        |          |
|                              | 0.3         | no change                | Htr7 KO|          |
|                              | 0.6         | no change                |        |          |
|                              | 1           | −1.1 °C (30′)            |        |          |

Note: 5-CT—5-carboxamidotryptamine maleate; *—background is 50%129SvEv/50% C57Bl/6J; for the others—C57BL/6J; ns—result is not significant.

It is noteworthy that the basal body temperatures in Htr7KO and WT animals are the same. The absence of a difference in body temperature between Htr7KO and WT animals is noted by most authors who worked with such animals [242–244]. This indicates either powerful compensatory processes occurring in the thermoregulation system, if its really important link has been removed, or weak significance of the 5-HT$_7$ receptor in maintaining the body’s temperature balance. These data undoubtedly draw attention to the question of the 5-HT$_7$ receptor role in thermoregulation, but so far only the integral parameter—body temperature—has come to the attention of researchers.

It is interesting to compare the results of Sugimoto et al. [182] and Hedlund et al. [242]. These authors used the property of peripherally administered 5-HT to induce hypothermia in experimental animals. They treated animals with the same dose of 5-HT and obtained a similar hypothermic effect. However, in the study of Sugimoto et al. [182], this effect was blocked by 5-HT$_2$ receptor antagonists, and in the one by Hedlund et al. [242], its emergence in mutant animals was prevented by the absence of 5-HT$_7$ receptors. Thus, the question of what is the proportion of 5-HT$_2$ and 5-HT$_7$ receptors in the hypothermic effect of peripherally administered 5-HT remains open. It is necessary to emphasize that a high dose of 5-CT (3 mg/kg, i.p.) in the experiments of Hedlund et al., [242] caused hypothermia even in animals lacking 5-HT$_7$ receptors, which suggests that other 5-HT receptors also took part in these processes.
The hypothermic effect of 5-HT₁₄ receptors agonist 8-OH-DPAT, which have developed after its administration in a stable, dose-dependent manner and regardless of the route of administration (see above), was also tested for the possible involvement of 5-HT₇ receptors. 8-OH-DPAT does indeed have an affinity to both of these receptors: its pKi = 8.4–9.4 (for 5-HT₁₄ human); 7.3–7.5 (for 5-HT₇ rat); 6.3–7.6 (for 5-HT₇ human); 6.6 (for 5-HT₇ mouse) [89]. Studies of the 5-HT₇ receptors’ role in the hypothermic effect of 8-OH-DPAT were carried out in mice (including those with Htr7 knockout) and in rats (Table 9). As expected, 8-OH-DPAT dose-dependently decreased body temperature in experimental animals (and at high doses even in Htr7KO mice). The pre-administration of 5-HT₁₄ and 5-HT₇ receptor antagonists, separately or together, with varying success, depending on their dose, weakened the hypothermic effect of 8-OH-DPAT. The general conclusion from these studies was that both receptors may be involved in the hypothermic effect of 8-OH-DPAT. Taking into account the data from recent years, when joint localization of these receptors, their ability to form heterodimers and mutual influence were shown, this conclusion does not seem strange, but indicates the need for a thorough study of these mutual influences and their role for the organism as a whole. Moreover, the data indicating that 8-OH-DPAT-induced hypothermia was a result only of 5-HT₁₄ receptor activation have already been obtained [30] (see below).

Table 9. Impact of pretreatment with 5-HT₇ and 5-HT₁₄ antagonists on hypothermic effects of 5-CT and 8-OH-DPAT in warm-blooded animals.

| Pretreatment Compound | Main Hypothermic Effect | Joint Effect of Two Compounds | Object | References |
|-----------------------|-------------------------|-------------------------------|--------|------------|
| SB-269970-A 3 mg/kg (i.p.) 60' | 5-CT 0.3 mg/kg (i.p.) −1.8 °C (75') | −0.4 °C | Guinea pig | [239] |
| SB-656104-A 3 mg/kg (i.p.) 60' | 5-CT 0.3 mg/kg (i.p.) −1.9 °C | −0.7 °C | Guinea pig | [240] |
| WAY100635 0.1; 0.3; 1 mg/kg (i.p.) 30' | 5-CT 0.3 mg/kg (i.p.) ≈−1.8 °C | ≈−1.4 °C | | |
| SB 258719 5; 10 mg/kg (i.p.) 20 mg/kg (i.p.) 30' | 5-CT 0.3 mg/kg (i.p.) ≈−1.7 °C | ≈−0.2 °C | Swiss Webster mice | [241] |
| SB-269970 1 mg/kg (i.p.) 3 mg/kg (i.p.) 10; 30 mg/kg (i.p.) 30' | 5-CT 0.3 mg/kg (i.p.) | −1.2 °C | | |
| | | −0.6 °C | | |
| | | −0.4 °C | | |
Table 9. Cont.

| Pretreatment | Dose (Route of Administration) | Time Interval | Compound | Dose (Route of Administration) | AT body (Time of Effect) | Object | References |
|--------------|--------------------------------|---------------|----------|--------------------------------|----------------------------|--------|------------|
| WAY-100135   | 1 mg/kg (i.p.)                 | 20'           | 8-OH-DPAT| 0.3 mg/kg (i.p.)               | −2°C (30')                 |        |            |
|              | 10 mg/kg (i.p.)                |               |          | 0.3 mg/kg (i.p.)               | −1.6°C                     |        |            |
|              |                                |               |          | 0.6 mg/kg (i.p.)               | −0.5°C                     | Sprague-Dawley rats | [75]       |
| SB-269970    | 0.3 mg/kg (i.p.)               | 20'           | 8-OH-DPAT| 0.3 mg/kg (i.p.)               | −1.2°C                     |        |            |
|              | 3 mg/kg (i.p.)                 |               |          | 0.5 mg/kg (i.p.)               | −0.6°C                     |        |            |
|              |                                |               |          | 1 mg/kg (i.p.)                 | −1.9°C (30')               | C57Bl6−/− |            |
|              |                                |               |          | 0.3 mg/kg (i.p.)               | −1.1°C                     |        |            |
|              |                                |               |          | 0.6 mg/kg (i.p.)               | −1.2°C                     |        |            |
|              |                                |               |          | 1 mg/kg (i.p.)                 | −1.1°C                     |        |            |
| WAY-100135   | 10 mg/kg (i.p.)                | 30'           | 8-OH-DPAT| 0.3 mg/kg (i.p.); 0.6 mg/kg (i.p.; 1 mg/kg (i.p.) | no change C57Bl6+/+        |        |            |
|              |                                |               |          | no change C57Bl6+/−             |                            |        |            |
| SB-269970    | 10 mg/kg (i.p.)                | 30'           | 8-OH-DPAT| 0.3 mg/kg (i.p.)               | no change                  |        |            |
|              |                                |               |          | 0.6 mg/kg (i.p.)               | −0.7°C (30')               | C57Bl6+/+ | [75]       |
|              |                                |               |          | 1 mg/kg (i.p.)                 | −1.2°C (30')               | C57Bl6+/− |            |
|              |                                |               |          | 0.3 mg/kg (i.p.)               | −1.5°C (30')               |        |            |
|              |                                |               |          | 0.6 mg/kg (i.p.)               | no change                  |        |            |
|              |                                |               |          | 1 mg/kg (i.p.)                 | −1.1°C (30')               |        |            |
| WAY-100635   | 0.005 mg/kg, s.c.              | 8-OH-DPAT     |          | −3.4°C (30')                   |                            | Sprague-Dawley rats | [245]    |
|              |                                |               |          | −2°C                            |                            |        |            |
| SB-269970    | 0.1 mg/kg (i.p.)               | 8-OH-DPAT     |          | −3.4°C                          |                            |        |            |
|              | 0.5 mg/kg (i.p.)               |               |          | −2.7°C                          |                            |        |            |
|              | 1 mg/kg (i.p.)                 |               |          | −2.3°C                          |                            |        |            |

Note: All compound used for pretreatment did not change animal’s body temperature when injected alone or together; AT body—change in body temperature; SB-269970-A—3-[(2R)-2-[2-(4-methylpiperidin-1-yl)ethyl]pyrrolidine-1-sulfonyl]phenol; SB-656104-A—6-[(2R)-2-[2-(4-chlorophenoxo)pyrrolidin-1-yl]ethyl]pyrrolidin-1-yl]sulfonyl-1H-indole; WAY1000635—N-[2-[(2-methoxyphenyl)piperazin-1-yl]-1H-indole-1-yl]ethyl-N-pyridin-2-ylcyclohexanecarboxamide; SB-258719—N,N-dimethyl-N-[2R]-4-(4-methylpiperidin-1-yl)butan-2-yl]benzenesulfonamide; WAY-100135—(S)-N-tert-butyl-3-(4-(2-methoxyphenyl)piperazine-1-yl)-2-phenylpropanamide; DR-4004—2a-[4-(4-phenyl-3,6-dihydro-2H-pyridin-1-yl]butyl]-1,3,4,5-tetrahydrobenzo[cd]indol-2-one.
Selective agonists of 5-HT7 receptors were developed somewhat later than antagonists, and their properties are still being refined [246]. The effect of one of the 5-HT7 receptor agonists, N-(4-cyanophenylmethyl)-4-(2-diphenyl)-1-piperazinehexanamide (LP-211), on animal body temperature was investigated by Hedlund et al. [243]. The object of the study was mice—WT and Htr7KO. LP-211 was administered i.p. at doses of 3, 10, and 30 mg/kg. The dose of 3 mg/kg did not lead to a change in body temperature in animals of both genotypes, and 30 mg/kg reduced temperature in all animals, although in animals lacking 5-HT7 receptors this decrease was less significant both in magnitude and in duration. Selective 5-HT7 receptor antagonist 3-[(2R)-2-[4-methylpiperidin-1-yl]ethyl]pyrrolidine-1-sulfonyl]phenol (SB-269970) blocked the LP-211 effect on body temperature, confirming that a decrease in temperature was the result of 5-HT7 receptors activation. WAY-100135 did not induce any changes in the LP-211 effect on body temperature confirming the absence of 5-HT1A receptors participation in this hypothermia. Brenchat et al. [244] tried to reveal the temperature effect of other 5-HT7 receptor agonists: (2S)-N,N-dimethyl-5-(1,3,5-trimethylpyrazol-4-yl)-1,2,3,4-tetrahydrophthalen-2-amine (AS-19), 2-(2-(dimethylamino)ethyl)-4-(1,3,5-trimethyl-1H-pyrazol-4-yl)phenyl]-ethyl]-amine dihydrochloride (E55888). The objects of the study were also WT and Htr7KO mice. Agonists were injected s.c. at the doses of 10 and 20 mg/kg. The compounds reduced body temperature in animals: AS-19 (20 mg/kg) in WT mice—by 3.8 °C, in Htr7KO—by 2.4 °C; E57421 (20 mg/kg)—by 1.1 °C in WT and by 2.3 °C in Htr7KO, that is under the influence of E57421, the temperature drop in WT was less than that in Htr7KO. E55888 (20 mg/kg) did not cause change in body temperature of animals. At a dose of 10 mg/kg, neither AS-19 nor E57421 had any effect on body temperature. The authors believed that the reason for hypothermia development under AS-19 and E57421 in animals without 5-HT7 receptors is the nonspecific ligand binding to other 5-HT receptors. Trying to explain the lack of temperature effect in E55888, the most selective 5-HT7 receptor agonist in this study, the authors suggested that 5-HT7 receptors activation alone is not enough to affect body temperature [244]. However, it seems that an explanation for this was found in the work by Naumenko et al. [30].

Naumenko et al. [30] worked with 5-HT7 receptors agonist 4-[2-(methylthio)phenyl]-N-(1,2,3,4-tetrahydro-1-naphthalenyl)-1-piperazinehexanamide (LP-44). To examine its effect on body temperature, they used not only a range of doses, but also different routes of their administration: i.c.v. and i.p.. I.c.v. administration of LP-44 produced a considerable dose-dependent hypothermic response. Pick effect of the maximum used dose (41.0 nmol) was observed between 15 and 30′ after injection and reached more than a 3 °C decrease. This effect was significantly attenuated by pretreatment with SB-269970 (16.1 fmol, i.c.v.). In contrast to i.c.v. administration, i.p. injection of LP44 in a wide range of doses (1.0, 2.0, and 10.0 mg/kg) failed to affect body temperature. Based on these findings, the authors concluded that central, rather than peripheral, 5-HT7 receptors are implicated in regulation of hypothermia. This result, presumably, explains why the highly selective 5-HT7 receptors agonist E55888, administered peripherally, did not affect body temperature of animals [244]. Although the review of DiPilato et al. [246] states that E55888 is brain penetrant, it also notes that its pharmacokinetic data have not been studied well enough. So, it may be assumed that the compound did not have enough time to get into the brain and realize its effect. Naumenko et al. [30] also showed that LP-44 does not affect 5-HT1A receptors: 5-HT1A receptors antagonist WAY-100635 did not attenuate LP-44-induced hypothermia. That is, LP-44-induced hypothermia is the effect of activating only 5-HT7 receptors. At the same time, blockade of 5-HT7 receptors with the selective antagonist SB 269970 produced no effect on 8-OH-DPAT-induced hypothermia, nor on mCPBG (5-HT3 receptors)-induced hypothermia. In general, the obtained results allowed the authors to formulate the following conclusions: “1) 8-OH-DPAT specifically binds with the 5-HT1A receptor; 2) the central 5-HT7 receptor plays an essential role in the mechanism of thermoregulation independent of 5-HT1A and 5-HT3 receptors” [30].
It seems necessary to take into consideration and discuss in more detail one more fact discovered by Naumenko et al. [30], which, perhaps, was not discussed well enough in the work. The hypothermic effect of centrally administered 5-HT was not altered by the 5-HT$_7$ receptor blockade. This indicates that for the natural ligand (albeit in the situation of an artificial increase of its concentration in the brain), the 5-HT$_7$ receptor is not a “first line of response” receptor regarding body temperature changes. However, this fact can be also explained by the too high dose of 5-HT used (61.7 nmol). Although the authors of the study wrote that they had chosen the dose very carefully, in the experiments of Yamada et al. [247], the more pronounced temperature effect developed in response to the 5-HT dose that was six times smaller (10 nmol, i.c.v.). So, these results seem to demand further investigation.

Information on how exactly 5-HT$_7$ receptors are involved in thermoregulation, whose processes of heat production and/or heat loss they affect, is given so far only in two works: Madden and Morrison [124,125]. These authors investigated the role of the intermedio-lateral (IML) nucleus (column) of the spinal cord in sympathetic regulation of BAT. They found that the blockade of 5-HT$_7$ receptors in this region (microinjections of SB 269970) partially reduces BAT SNA, induced by some pharmacological drugs [124] or cold [125]. These results indicate that 5-HT$_7$ receptors in the spinal cord contribute to increases in BAT SNA and thermogenesis, i.e., they act oppositely to 5-HT$_7$ receptors in the brain.

Certainly the question arises: does this ability of 5-HT$_7$ receptors to lower the body temperature of warm-blooded animals found in pharmacological studies have any physiological significance? Are there any facts confirming the participation of 5-HT$_7$ receptors in maintaining body temperature in natural conditions? At the moment, unfortunately, there are very few studies shedding light on these questions.

In one of them, Kose et al. [248] tried to elucidate the role of 5-HT$_7$ receptors in maintaining body temperature during LPS-induced hyperthermia in mice. It was found that 5-HT$_7$ receptor agonist AS19 not only prevented the development of LPS-induced hyperthermia, but also led to a decrease in body temperature in experimental animals as compared to control ones (treated only by vehicle). 5-HT$_7$ receptor antagonist (SB269970) promoted more pronounced hyperthermia even compared to LPS-treated animals. In other words, 5-HT$_7$ receptors activation prevented the development of fever, and their blockade aggravated the fever. In general, based on known data on the effect of this receptor type on body temperature, such a result is expected. However, perhaps the most interesting fact shown in this work is that LPS increased Htr7 expression in hypothalamus compared to the level of control animals. Correlation between the level of animal body temperature and the Htr7 expression level was not found. This suggests that body temperature is not a trigger for increasing of Htr7 expression in this study. However, the fact of an expression increase indicates active involvement of the 5-HT$_7$ receptor in organism response to the bacterial toxin. Whether the task of the 5-HT$_7$ receptor in response to LPS was: to reduce body temperature elevation or to mediate immune reaction is still unclear. Nevertheless this is an example of an active reaction of the receptor to external nonpharmacological influence.

Gargaglioni et al. [249] investigated the possible role of 5-HT$_7$ receptors in the development of hypoxic hypothermia. It is known that hypothermia, accompanied by a decrease in metabolism, is an adaptive response used by many species of animals, especially small ones, to experience adverse conditions. Hypoxic hypothermia is a physiological response to the reduction of O$_2$ in inhaled air. The authors induced hypothermia in experimental animals (rats) by placing them in an atmosphere with low O$_2$ content. Blockade of 5-HT$_7$ receptors by microinjection of SB269970 into anteroventral preoptic region (AVPO) caused a dose-dependent reduction in hypoxia-induced hypothermia. Microinjections of SB269970 into extra-AVPO region had no effects. So, the authors demonstrated not only the participation of 5-HT$_7$ receptors in the development of hypoxic hypothermia, but also the precise region of the brain responsible for it.

Comparison of the known facts about the localization and physiological functions of 5-HT$_7$ receptors, such as their high concentration in the supraoptic nucleus of hypothalamus,
participation in regulation of circadian rhythms, sleep, changes in body temperature, suggests a possible role of these receptors in such adaptive reactions as daily torpor and hibernation. Hrvatin et al. [250] name torpor and hibernation “the most fascinating adaptations of warm-blooded animals, endowing them with the ability to survive in harsh environments otherwise incompatible with life”. Nevertheless, studies on the role of 5-HT7 receptors in these amazing processes are still awaiting their authors.

5. General Discussion and Conclusions

Speaking about the role of 5-HT receptors in thermoregulation, one should remember that the thermoregulation system, in addition to effector links, also has an afferent one, i.e., those through which the temperature information reaches the center. Unfortunately, studies on the effect of 5-HT receptors on this link of the thermoregulation system seem to be absent or unavailable. However, the possibility of such influence exists. It is confirmed by the effect of 5-HT receptors on pain sensitivity, including temperature pain sensitivity [244,251–255]. In addition, it was shown that microiontophoretic application of 5-HT suppresses the response of dorsal horn neurons to thermal skin stimulation [256]. This indicates a possible involvement of 5-HT receptors in the modulation of the temperature afferent signal. It is not yet clear what types of 5-HT receptors are involved in this process, but the possibility of their influence on temperature sensitivity is beyond doubt.

Certainly the intriguing question is the question of the mutual influence (interaction) of 5-HT receptors in the maintenance of body temperature. However, the answer on this question is not easy. Firstly, due to the fact that the results of receptor interactions at the cellular level studies (see [38,257]) or at the level of hypothalamic nuclei ones [258,259], as a rule, do not include studies of temperature effects. Secondly, when only temperature effects are investigated, the results of the actions practically represent the sum of opposite (or unidirectional) influences. So, for example, under the influence of 5-HT2 receptor activation, 5-HT1A-induced hypothermia is less pronounced, and under the 5-HT2 receptor blockade—enhanced [56,63,179] and vice versa: hyperthermia caused by 5-HT2 receptors activation decreases upon 5-HT1A receptors activation, and upon blockade of these receptors—increases [168]. At what stage is the “summation” of receptor effects—already at the level of the effector or earlier—at the level of central interactions, is difficult to say. The fact that, under the influence of some 5-HT receptors, behavioral reactions mediated by other receptors also change [49,179], allows to conclude that the interaction of receptors occurs at the center level. However, it would be desirable that changes in the characteristics of one receptor under the influence of another, significant for thermoregulation, but found in the study of behavior, were confirmed in appropriate experiments.

Thus, a lot of data has been collected concerning the effect of 5-HT receptors on body temperature of warm-blooded animals and on processes associated with its maintenance. It has been established that the pharmacological activation of 5-HT1A, 5-HT3, and 5-HT7 types causes a decrease in body temperature, whereas 5-HT2 activation causes its increase. The following fact is rather interesting. Thermoregulatory reactions aimed at increasing body temperature of a warm-blooded animal are controlled only by 5-HT2 receptors, which are similar in structure and signal transmission, while a decrease is controlled by three types of receptors that differ significantly not only in intracellular signal transmission (like 5-HT1A and 5-HT7), but also are the compounds of different classes: GPCRs (5-HT1A and 5-HT7) and the ion channel (5-HT3). Duplication of control over some parameter both in technology and in physiology testifies to the significance of this parameter. The fact that 5-HT receptors of three different types are “targeted” to reduce body temperature of a warm-blooded organism, emphasizes the fragility of the state of homeothermy and its balancing near the dangerous limit of overheating. From death due to hypothermia, warm-blooded animals (even humans) are separated by more than 15 °C, and from death due to overheating by just over 5 °C [1]. It seems that the 5-HT system with its three types of receptors, the activation of which contributes to a decrease in body temperature, stands on the protection of warm-blooded organism just from overheating. It would be useful to illustrate this
suggestion. The results of Ishiwata et al. [260] may serve as a good illustration. These authors simultaneously recorded the content of monoamines (norepinephrine, dopamine and 5-HT) in the ventral tegmental area, body temperature (integral parameter), and tail temperature (for estimation of heat loss intensity) in non-anesthetized rats. The animals, after measuring these parameters at room temperature (23 °C), were subjected to 2 h of temperature exposure: heat (35 °C) or cold (5 °C). Under exposure to heat, an increase in body temperature (≈+1.5 °C), an increase in tail temperature (≈+10 °C), and an increase in the 5-HT level (by more than 30%) were recorded. There were no changes in the concentration of other monoamines. These results clearly confirm that it is 5-HT system that responds to exposure to heat. The next step was to find out the physiological meaning of the observed change. For this purpose, the authors modeled changes in the concentration of 5-HT in the studied brain area by injecting an inhibitor of its reuptake. An increase in the concentration of 5-HT was accompanied by a decrease in body temperature of a rat due to the activation of heat loss processes (an increase in the temperature of the tail). This is very similar to the processes occurring when 5-HT1A and 5-HT3 receptors are activated. Exposure to cold in these experiments turned out to be more gentle, although its duration was the same as of one to heat. Body temperature of animals even increased, apparently, due to heat loss limitation, judging by the temperature of the tail, the concentration of monoamines did not change. That is, an increase in the ambient temperature by 12 °C had a more powerful effect on the rat’s organism than a decrease by 18 °C. A similar pattern is true not only for a rat, but also for other warm-blooded animals [91–93]. So the presence of three types of 5-HT receptors, the activation of which is aimed at lowering body temperature, is well justified.

Knowledge of the subtle mechanisms of influence on body temperature, which are inherent in the organism by nature, opens up prospects for a sparing effect on the body to obtain a state of hypo- or hyperthermia, if it is necessary (for example, an attempt to obtain a state of hypothermia using only external cooling invariably encounters intense resistance from the thermoregulatory system, see Burton and Edholm [261]). The areas where this knowledge can be used are the widest. It may be a decrease in postoperative tremors, and the possibility of influencing inflammatory processes, provoking hyperthermia to combat certain cancers or viruses and vice versa, introducing an injured patient into hypothermia to prevent damage to vital organs (brain, heart) during its transportation to clinics, prevention of radiation damage and, of course, the use of hypometabolic states in the conquest of interplanetary space [262–265].

In conclusion, it should be noted that until now, among numerous excellent reviews describing 5-HT receptors, only one (31) was devoted specially to the role of 5-HT receptors in body temperature maintenance. The ability of these receptors to change body temperature in warm-blooded animals was usually only mentioned in previous reviews, but not discussed. Present manuscript fills this gap; however, the task of any review is not only to summarize the known material (Figure 1), but also to indicate what has not yet been done. Changes in temperature homeostasis parameters under pharmacological influences have been studied to the greatest extent. The interpretation of the results obtained with the help of genetic modifications must always be approached with caution, taking into account possible compensatory processes in the body. Moreover, experimental evidence is needed for the participation of 5-HT receptors in thermoregulatory reactions under natural (or as close to natural as possible) conditions.
Figure 1. Phenomenon—changes in body temperature of warm-blooded organism—and mechanisms of its appearance—physiological processes of heat loss and heat production that stimulation (inhibition) under 5-HT receptors activation lead to observed phenomenon. Red arrows—stimulation of physiological processes and increase of body temperature. Blue arrows—inhibition of physiological processes and decrease of body temperature.

Funding: The study was supported by budgetary funding for basic scientific research (theme No AAAA-A21-121011990039-2).

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Acknowledgments: The author is grateful to Anna Evtushenko for kindly preparing illustration.

Conflicts of Interest: The author declares no conflict of interest.

References

1. Ivanov, K.P. The principles of energetics of organism: Theoretical and practical aspects. In Modern Problems, Enigmas and Paradoxes of Regulation of Energetical Balance; Nauka: St-Petersburg, Russia, 2001; Volume 3, p. 278.
2. Romanovsky, A.A. The thermoregulation system and how it works. In Handbook of Clinical Neurology, Thermoregulation: From Basic Neuroscience to Clinical Neurology, Part I; Romanovsky, A.A., Ed.; 3rd Series; Elsevier: Amsterdam, The Netherlands, 2018; Volume 156, pp. 3–43. [CrossRef]
3. Tan, C.L.; Knight, Z.A. Regulation of Body Temperature by the Nervous System. Neuron 2018, 98, 33-48. [CrossRef] [PubMed]
4. Parent, A. Comparative anatomy of the serotoninergic systems. J. Physiol. 1981, 77, 147–156.
5. Gaspar, P.; Lillesaar, C. Probing the diversity of serotonin neurons. Philos. Trans. R. Soc. Lond. B Biol. Sci. 2012, 367, 2382–2394. [CrossRef] [PubMed]
6. Twarog, B.M.; Page, I.H. Serotonin content of some mammalian tissues and urine and a method for its determination. Am. J. Physiol. 1953, 175, 157–161. [CrossRef]
7. Amin, A.H.; Crawford, T.B.B.; Gaddum, J.H. The distribution of substance p and 5-hydroxytryptamine in the central nervous system of the dog. *J. Physiol.* **1954**, *126*, 596–618. [CrossRef]

8. Bachtold, H.; Pletscher, A. Einfluss von isonikotinsaurehydraziden auf den Verlauf der Korpertemperatur nach Reserpin, Monoaminen und Chlorpromazin. *Experientia* **1957**, *13*, 163–165. [CrossRef]

9. Hillegaart, V. Effect of local application of 5-HT and 8-OH-DPAT into the dorsal and median raphe nuclei on core temperature in the rat. *Psychopharmacology* **1991**, *103*, 291–296. [CrossRef] [PubMed]

10. Feldberg, W.; Myers, R.D. A new concept of temperature regulation by amines in the hypothalamus. *Nature* **1963**, *200*, 1325–1326. [CrossRef]

11. Myers, R.D. Serotonin and thermoregulation: Old and new views. *J. Physiol.* **1981**, *77*, 505–513.

12. Bligh, J.; Cottle, W.H.; Maskrey, M. Influence of ambient temperature on the thermoregulatory responses to 5-hydroxytryptamine, noradrenaline and acetylcholine injected into the lateral cerebral ventricles of sheep, goats and rabbits. *J. Physiol.* **1971**, *212*, 377–392. [CrossRef]

13. Gurin, V.N. *Central Mechanisms of Thermoregulation*; USSR: Minsk, Belarus, 1980; p. 127.

14. Koriakina, L.A.; Kulikov, A.V.; Figurova, M.I.; Popova, N.K. Effect of cold on the brain serotonin system and the corticosteroid level of the blood in different strains of mice. *Fiziol. Zhurnal SSSR Im. IM Sechenova* **1985**, *71*, 422–427.

15. Popova, N.K.; Konusova, A.V. Brain and peripheral effects of serotonin on thermoregulation. *Biog. Amines* **1985**, *3*, 125–134.

16. Sitnikov, V.D.; Kudriavtseva, N.N.; Iakimenko, M.A.; Popova, N.K. Effect of serotonin on thermoregulation in normothermic hibernators and during arousal from deep hypothermia. *Biull. Eksph. Biol. Med.* **1986**, *101*, 5–7. [CrossRef]

17. Zeisberger, E. The roles of monoaminergic neurotransmitters in thermoregulation. *Can. J. Physiol. Pharmacol.* **1987**, *65*, 1395–1401. [CrossRef]

18. Saudou, F.; Hen, R. 5-Hydroxytryptamine receptor subtypes: Molecular and functional diversity. *Adv. Pharmacol.* **1994**, *30*, 327–380.

19. Barnes, N.M.; Sharp, T. A review of central 5-HT receptors and their function. *Neuropharmacology* **1999**, *38*, 1083–1152. [CrossRef]

20. Peroutka, S.J.; Howell, T.A. The molecular evolution of G protein-coupled receptors: Focus on 5-hydroxytryptamine receptors. *Neuropharmacology* **1994**, *33*, 319–324. [CrossRef]

21. Hoyer, D.; Hannon, J.P.; Martin, G.R. Molecular, pharmacological and functional diversity of 5-HT receptors. *Pharmacol. Biochem. Behav.* **2002**, *71*, 533–554. [CrossRef]

22. Hannon, J.; Hoyer, D. Molecular biology of 5-HT receptors. *Behav. Brain Res.* **2008**, *195*, 198–213. [CrossRef]

23. Nichols, D.E.; Nichols, C.D. Serotonin Receptors. *Chem. Rev.* **2008**, *108*, 1614–1641. [CrossRef]

24. Filip, M.; Bader, M. Overview on 5-HT receptors and their role in physiology and pathology of the central nervous system. *Pharmacol. Rep.* **2009**, *61*, 761–777. [CrossRef]

25. Andrade, R.; Barnes, N.M.; Baxter, G.; Bockaert, J.; Branchek, T.; Butler, A.; Cohen, M.L.; Dumuis, A.; Eglen, R.M.; Gothert, M.; et al. 5-Hydroxytryptamine receptors (version 2019.4) in the IUPHAR/BPS guide to pharmacology database. *ILPHAR/BPS Guide Pharmacol. 2019*, 2019. [CrossRef]

26. Sharp, T.; Barnes, N.M. Central 5-HT receptors and their function; present and future. *Neuropharmacology* **2020**, *177*, 108155. [CrossRef]

27. Barnes, N.M.; Ahern, G.P.; Becamel, C.; Bockaert, J.; Camilleri, M.; Chaumont-Dubel, S.; Claeyens, S.; Cunningham, K.A.; Fone, K.C.; Gershon, M.; et al. International Union of Basic and Clinical Pharmacology. CX. Classification of Receptors for 5-hydroxytryptamine; Pharmacology and Function. *Pharmacol. Rev.* **2021**, *73*, 310–520. [CrossRef]

28. Popova, N.K.; Kulikov, A.V. Multiple serotonin receptors as a molecular background underlying the multifunctionality of serotonin. In *Successes of Functional Neurochemistry*; Dambilova, S.A., Arutjunjan, A.V., Eds.; St.-Petersburg University: St.-Petersburg, Russia, 2003; pp. 56–73.

29. Popova, N.K.; Naumenko, V.S. Polymorphism in 5-HT receptors as the background of serotonin functional diversity. *Ross. Fiziol. Zhurnal Im. IM Sechenova* **2010**, *96*, 778–786.

30. Naumenko, V.S.; Kondaurova, E.M.; Popova, N.K. On the role of brain 5-HT7 receptor in the mechanism of hypothermia: Comparison with hypothymia mediated via 5-HT1A and 5-HT3 receptor. *Neuropharmacology* **2011**, *61*, 1360–1365. [CrossRef]

31. Ishiwata, T. Role of serotoninergic system in thermoregulation in rats. *J. Phys. Fit. Sports Med.* **2014**, *3*, 445–450. [CrossRef]

32. Ensemble Genome Browser: https://www.ensembl.org/index.html (accessed on 5 November 2021).

33. Ou, X.M.; Jafar-Nejad, H.; Storring, J.M.; Meng, J.H.; Lemonde, S.; Albert, P.R. Novel dual repressor elements for neuronal cell-specific transcription of the rat 5-HT1A receptor gene. *J. Biol. Chem.* **2000**, *275*, 8161–8168. [CrossRef]

34. Zhong, P.; Ciaramello, R.D. Transcriptional regulation of hippocampal 5-HT1A receptors by corticosteroid hormones. *Mol. Brain Res.* **1995**, *29*, 23–34. [CrossRef]

35. Meijer, O.C.; Cole, T.J.; Schmid, W.; Schütz, G.; Joels, M.; De Kloet, E.R. Regulation of hippocampal 5-HT1A receptor mRNA and binding in transgenic mice with a targeted disruption of the glucocorticoid receptor. *Mol. Brain Res.* **1997**, *46*, 290–296. [CrossRef]

36. Ou, X.M.; Storring, J.M.; Kushwaha, N.; Albert, P.R. Heterodimerization of mineralocorticoid and glucocorticoid receptors at a novel negative response element of the 5-HT1A receptor gene. *J. Biol. Chem.* **2001**, *276*, 14299–14307. [CrossRef] [PubMed]

37. Masson, J.; Emerit, M.B.; Hamon, M.; Darmon, M. Serotonergic signaling: Multiple effectors and pleiotropic effects. *WIREs Membr. Transp. Signal* **2012**, *1*, 685–713. [CrossRef]
38. Naumenko, V.S.; Popova, N.K.; Lacivita, E.; Leopoldo, M.; Ponimaskin, E.G. Interplay between serotonin 5-HT1A and 5-HT7 receptors in depressive disorders. CNS Neurosci. Ther. 2014, 20, 582–590. [CrossRef]

39. Weissman-Nanopoulos, D.; Mach, E.; Marge, J.; Demasse, Y.; Pujol, J.-F. Evidence for localization of 5-HT1A binding sites on serotonin containing neurons in the raphe dorsalis and raphe centralis nuclei on the rat brain. Neurochem. Int. 1985, 7, 1061–1072. [CrossRef]

40. Verge, D.; Daval, G.; Patey, A.; Gozlan, H.; El Mestikawy, S.; Hammon, M. Presinaptic 5-HT autoreceptors on serotonergic cell bodies and/or dendrites but not terminals are of the 5-HT1A subtype. Eur. J. Pharmacol. 1985, 113, 463–464. [CrossRef]

41. Hjorth, S.; Magnusson, T. The 5-HT1A receptor agonist, 8-OH-DPAT, preferentially activates cell body 5-HT autoreceptors in rat brain In Vivo. Naunyn Schmiedebergs Arch. Pharmacol. 1988, 338, 463–471. [CrossRef] [PubMed]

42. Pompeiano, M.; Palacios, J.M.; Mengod, G. Distribution and cellular localization of mRNA coding for 5-HT1A receptor in the rat brain: Correlation with receptor binding. J. Neurosci. 1992, 12, 440–453. [CrossRef]

43. Burnet, P.F.; Eastwood, S.L.; Harrison, P.J. Detection and quantitation of 5-HT1A and 5-HT2A receptor mRNAs in human hippocampus using a reverse transcription-polymerase chain reaction (RT-PCR) technique and their correlation with binding site densities and age. Neurosci. Lett. 1994, 178, 85–89. [CrossRef]

44. Kia, H.K.; Miquel, M.C.; Brisorgueil, M.J.; Daval, G.; Riad, M.; El Mestikawy, S.; Hamon, M.; Vergé, D. Immunocytochemical localization of serotonin1A receptors in the rat central nervous system. J. Comp. Neurol. 1996, 365, 289–305. [CrossRef]

45. Knapp, D.J.; Overstreet, D.H.; Crews, F.T. Brain 5-HT1A receptor autoradiography and hypothalamic responses in rats bred for differences in 8-OH-DPAT sensitivity. Brain Res. 1998, 782, 1–10. [CrossRef]

46. Popova, N.K.; Naumenko, V.S. 5-HT1A receptor as a key player in the brain 5-HT system. Rev. Neurosci. 2013, 24, 191–204. [CrossRef] [PubMed]

47. Naumenko, V.S.; Popova, N.K.; Plyusnina, I.Z.; Kulikov, A.V. Reduction in 5-HT1A receptor density, 5-HT1A mRNA expression, and functional correlates for 5-HT1A receptors in genetically defined aggressive rats. J. Neurosci. Res. 2005, 80, 286–292. [CrossRef]

48. Kondaurova, E.M.; Bazovkina, D.V.; Kulikov, A.V.; Popova, N.K. Selective breeding for catalepsy changes the distribution of microsatellite D13Mit76 alleles linked to the 5-HT serotonin receptor gene in mice. Genes Brain Behav. 2006, 5, 596–601. [CrossRef]

49. Naumenko, V.S.; Bazovkina, D.V.; Kondaurova, E.M.; Zubkov, E.A.; Kulikov, A.V. The role of 5-HT2A receptor and 5-HT2A/5-HT1A receptor interaction in the suppression of catalepsy. Genes Brain Behav. 2010, 9, 519–524. [CrossRef] [PubMed]

50. Cryan, J.F.; Kelliber, P.; Kelly, J.P.; Leonard, B.E. Comparative effects of serotonergic agonists with varying efficacy at the 5-HT1A receptor on core body temperature: Modification by the selective 5-HT1A receptor antagonist WAY100653. J. Psychopharmacol. 1999, 13, 278–283. [CrossRef]

51. Richardson-Jones, J.W.; Craige, C.P.; Guiard, B.P.; Stephen, A.; Metzger, K.L.; Kung, H.F.; Gardier, A.M.; Dranovsky, A.; David, D.J.; Beck, S.G.; et al. Distribution and cellular localization of serotonin1A receptors in the rat central nervous system. J. Comp. Neurol. 1996, 365, 1–10. [CrossRef]

52. Turcotte-Cardin, V.; Vahid-Ansari, F.; Luckhart, C.; Daigle, M.; Geddes, S.D.; Tanaka, K.F.; Hen, R.; James, J.; Merali, Z.; Beique, J.-C. Loss of adult 5-HT1A-like and GABA receptors in the dorsal raphe' nucleus of the rat. J. Neurosci. Res. 2005, 81, 1334–1346. [CrossRef]

53. Goodwin, G.M.; De Souza, R.J.; Green, A.R. The pharmacology of the hypothalamic response in mice to 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT): A model of presynaptic 5-HT1 receptor function. Neuropharmacology 1985, 24, 1187–1194. [CrossRef]

54. Hjorth, S. Hypothymia in the rat induced by the potent serotonergic agent 8-OH-DPAT. J. Neural Transm. 1985, 61, 131–135. [CrossRef]

55. Gudelsky, G.A.; Koenig, J.I.; Meltzer, H.Y. Thermo regulatory responses to serotonin (5-HT) receptor stimulation in the rat. Evidence for opposing roles of 5-HT1 and 5-HT3 receptors. Neuropharmacology 1986, 25, 1307–1313. [CrossRef]

56. De Souza, R.J.; Goodwin, G.M.; Green, A.R.; Heal, D.J. Effect of chronic treatment with 5-HT1 agonist (8-OH-DPAT and RU 24969) and antagonist (isapirone) drugs on the behavioural responses of mice to 5-HT1 and 5-HT2 agonists. Br. J. Pharmacol. 1986, 89, 377–384. [CrossRef]

57. Goodwin, G.M.; De Souza, R.J.; Green, A.R.; Heal, D.J. The pharmacology of the behavioural and hypothermic responses of rats to 8-hydroxy-2-(di-n-propylamino)-tetralin (8-OH-DPAT). Psychopharmacology 1987, 91, 506–511. [CrossRef]

58. Hutton, P.H.; Donohoe, T.P.; Curzon, G. Hypothermia induced by the putative 5-HT1A agonists LY165163 and 8-OHDPAT is not prevented by 5-HT deplet. Eur. J. Pharmacol. 1987, 143, 221–228. [CrossRef]

59. Higgins, G.A.; Bradbury, A.J.B.; Jones, J.; Oakley, N.R. Behavioural and biochemical consequences following activation of 5HT1-like and GABA receptors in the dorsal raphe’ nucleus of the rat. Neuropharmacology 1988, 27, 993–1001. [CrossRef]

60. Wozniak, K.M.; Aulakh, C.S.; Hill, J.L.; Murphy, D.L. The effect of 8-OH-DPAT on temperature in the rat and its modification by chronic antidepressant treatments. Pharmacol. Biochem. Behav. 1988, 30, 451–456. [CrossRef]

61. Nash, J.F.; Meltzer, H.Y.; Gudelsky, G.A. Antagonism of serotonin receptor mediated neuroendocrine and temperature responses by atypical neuroleptics in the rat. Eur. J. Pharmacol. 1988, 151, 463–469. [CrossRef]

62. Berendsen, H.H.; Broekkamp, C.L. Behavioural evidence for functional interactions between 5-HT-receptor subtypes in rats and mice. Br. J. Pharmacol. 1990, 101, 667–673. [CrossRef]
64. Bill, A.; Knight, M.; Forster, E.A.; Fletcher, A. Direct evidence for an important species difference in the mechanism of 8-OH-DPAT-induced hypothermia. Br. J. Pharmacol. 1991, 103, 1857–1864. [CrossRef]

65. Meller, E.; Chalﬁn, M.; Bohmaler, K. Serotonin 5-HT1A receptor-mediated hypothermia in mice: Absence of spare receptors and rapid induction of tolerance. Pharmacol. Biochem. Behav. 1992, 43, 405–411. [CrossRef]

66. Martin, K.F.; Phillips, I.; Hearson, M.; Prow, M.R.; Heal, D.J. Characterization of 8-OH-DPAT-induced hypothermia in mice as a 5-HT1A autoreceptor response and its evaluation as a model to selectively identify antidepressants. Br. J. Pharmacol. 1992, 107, 15–21. [CrossRef]

67. Zamfiri, O.; Broqua, P.; Baudrie, V.; Chaouloff, F. Effects of cold stress on some 5-HT1A, 5-HT1C and 5-HT2 receptor-mediated responses. Eur. J. Pharmacol. 1992, 219, 261–269. [CrossRef]

68. Fletcher, A.; Forster, E.A.; Bill, D.J.; Brown, G.; Cliffe, I.A.; Hartley, J.E.; Jones, D.E.; McLachlan, A.; Stanhope, K.J.; Critchley, D.J.; et al. Electrophysiological, biochemical, neuroendocrine and behavioural studies with 8-OHDPAT, a potent, selective and silent 5-HT1A receptor antagonist. Behav. Brain Res. 1996, 73, 337–353. [CrossRef]

69. Lin, M.T.; Tsay, H.J.; Su, W.H.; Chueh, F.Y. Changes in extracellular serotonin in rat hypothalamus affect thermoregulatory function. Am. J. Physiol. -Regul. Integr. Comp. Physiol. 1998, 274, R1260–R1267. [CrossRef]

70. Hensler, J.G.; Truett, K.A. Effect of chronic serotonin 5-HT2 receptor agonist or antagonist administration on serotonin-1A receptor sensitivity. Neuropsychopharmacology 1998, 19, 354–364. [CrossRef]

71. Gardier, A.M.; Gruwez, B.; Trillet, A.-C.; Jacquot, C.; Hen, R.; Bourin, M. Interaction between 5-HT1A and 5-HT1B receptors: Effects of 8-OH-DPAT-induced hypothermia in 5-HT1B receptor knockout mice. Eur. J. Pharmacol. 2001, 421, 171–175. [CrossRef]

72. Haddjeri, N.; Faure, C.; Lucas, G.; Mnie-Filali, O.; Chouvet, G.; Astier, B.; Renaud, B.; Blier, P.; Debonnel, G. In-vivo modulation of central 5-hydroxytryptamine (5-HT1A) receptor-mediated responses by the cholinergic system. Int. J. Neuropsychopharmacol. 2004, 7, 391–399. [CrossRef]

73. Hedlund, P.B.; Kelly, L.; Mazur, C.; Lovenberg, T.; Sutcliffe, J.G.; Bonaventure, P. 8-OH-DPAT acts on both 5-HT1A and 5-HT7 receptors to induce hypothermia in rodents. Eur. J. Pharmacol. 2004, 487, 125–132. [CrossRef]

74. Popova, N.K.; Naumenko, V.S.; Plyusnina, I.Z. The involvement of brain 5-HT1A autoreceptor response and its evaluation as a model to selectively identify antidepressants. Eur. J. Pharmacol. 1992, 219, 261–269. [CrossRef]

75. Popova, N.K.; Tibeikina, M.V.; Zaretsky, D.V.; DiMicco, J.A. 3,4-Methylenedioxymethamphetamine- and 8-hydroxy-2-di-n-propylamino- tetralin-induced hypothermia: Role and location of 5-hydroxytryptamine 1A receptors. Neuropsychopharmacology 1998, 19, 354–364. [CrossRef]

76. Watson, C.T. Comparison of relative potencies of i.v. and i.c.v. administered 8-OH-DPAT gives evidence of different sites of action for hypothermia, lower lip retraction and tail flicks. Eur. J. Pharmacol. 1992, 219, 261–269. [CrossRef]

77. Rusyniak, D.E.; Zaretsky, D.V.; Zaretsky, D.V.; DiMicco, J.A. 3,4-Methylenedioxymethamphetamine- and 8-hydroxy-2-di-n-propylamino-tetralin-induced hypothermia: Behavioral and functional correlates. Psychiat. Genet. 1996, 6, 107–117. [CrossRef]

78. Yamamoto, T.; Unoki, H.; Itoh, H.; Taka, M.; Nakanishi, S. Effects of corticosterone on 5-HT1A and 5-HT2 receptor binding and on the receptor-mediated behavioral responses of rats. Eur. J. Pharmacol. 1997, 333, 123–128. [CrossRef]

79. Richardson-Jones, J.W.; Craig, C.P.; Nguyen, T.H.; Taka, M.; Unoki, H.; Itoh, H.; Yamamoto, T.; Nakanishi, S. Effects of corticosterone on 5-HT1A and 5-HT2 receptor binding and on the receptor-mediated behavioral responses of rats. Eur. J. Pharmacol. 1997, 333, 123–128. [CrossRef]

80. Popova, N.K.; Tibeikina, M.V.; Zaretsky, D.V.; DiMicco, J.A. 3,4-Methylenedioxymethamphetamine- and 8-hydroxy-2-di-n-propylamino-tetralin-induced hypothermia: Role and location of 5-hydroxytryptamine 1A receptors. J. Pharmacol. Exp. Ther. 2007, 323, 477–487. [CrossRef]

81. Bagdy, G.; Huszár, F.; Tóth, J.; Kis, A.; Kónya, G. Electrophysiological, biochemical, neuroendocrine and behavioural studies with WAY-100635, a potent, selective and silent 5-HT1A receptor antagonist. Behav. Brain Res. 1996, 73, 337–353. [CrossRef]

82. Richardson-Jones, J.W.; Craig, C.P.; Nguyen, T.H.; Kung, H.F.; Gardier, A.M.; Dranovsky, A.; David, D.J.; Guiard, B.P.; Beck, S.G.; Hen, R.; et al. Serotonin-1A autoreceptors are necessary and sufficient for the normal formation of circuits underlying innate anxiety. J. Neurosci. 2011, 31, 6008–6018. [CrossRef]

83. IUPHAR/BPS Guide to Pharmacology. Available online: https://www.guidetopharmacology.org (accessed on 14 November 2021).

84. O’Connell, M.T.; Sarna, G.S.; Curzon, G. Evidence for postsynaptic mediation of the hypothermic effect of 5-HT1A receptor activation. Br. J. Pharmacol. 1992, 106, 603–609. [CrossRef] [PubMed]

85. Matsuda, T.; Kanda, T.; Seong, Y.H.; Baba, A.; Iwao, H. p-Chlorophenylalanine attenuates the putidary-adrenocortical response to 5-HT1A receptor agonist in mice. Br. J. Pharmacol. 1990, 181, 295–297. [CrossRef]

86. Blatter, R.; Seletti, B.; Gilbert, F.; Young, S.N.; Benkelfat, C. Serotonin(1A) receptor activation and hypothermia in humans: Lack of evidence for a presynaptic mechanism. Neuropsychopharmacology 2002, 27, 301–308. [CrossRef]

87. Richardson-Jones, J.W.; Craig, C.P.; Nguyen, T.H.; Kung, H.F.; Gardier, A.M.; Dranovsky, A.; David, D.J.; Guiard, B.P.; Beck, S.G.; Hen, R.; et al. Serotonin-1A autoreceptors are necessary and sufficient for the normal formation of circuits underlying innate anxiety. J. Neurosci. 2011, 31, 6008–6018. [CrossRef]

88. O’Connell, M.T.; Sarna, G.S.; Curzon, G. Evidence for postsynaptic mediation of the hypothermic effect of 5-HT1A receptor activation. Br. J. Pharmacol. 1992, 106, 603–609. [CrossRef] [PubMed]

89. IUPHAR/BPS Guide to Pharmacology. Available online: https://www.guidetopharmacology.org (accessed on 14 November 2021).

90. Koe, B.K.; Weissman, A. p-Chlorophenylalanine: A specific depletor of brain serotonin. J. Pharmacol. Exp. Ther. 1966, 154, 499–516.
Biomolecules 2021, 10, 4. Jansky, L. Humoral thermogenesis and its role in maintaining energy balance. [CrossRef]

117. Yakimenko, M.A. Muscular thermogenesis during adaptation to cold. In Bioenergetics and Temperature Homeostasis. Ivanov, K.P., Ed.; Nauka: Leningrad, Russia, 1972; Volume 30, pp. 137–152. [CrossRef]

108. Morrison, S.F. Activation of 5-HT_1A receptors in raphe pallidus inhibits leptin-evoked increases in brown adipose tissue thermogenesis. Am. J. Physiol. 2004, 286, R832–R837. [CrossRef]

Morrisson, S.F. Efferent neural pathways for the control of brown adipose tissue thermogenesis and shivering. In Thermoregulation: From Basic Neuroscience to Clinical Neurology, Part I; Romanovsky, A.A., Ed.; 3rd Series; Elsevier: Amsterdam, The Netherlands, 2018; Volume 156, pp. 281–303.

112. Nakamura, K. Afferent pathways for autonomic and shivering thermoeffectors. In Thermoregulation: From Basic Neuroscience to Clinical Neurology, Part I; Romanovsky, A.A., Ed.; 3rd Series; Elsevier: Amsterdam, The Netherlands, 2018; Volume 156, pp. 263–279.

110. Cannon, B.; Nedergaard, J. Brown adipose tissue: Function and physiological significance. Physiol. Rev. 2004, 84, 277–359. [CrossRef]

111. Oelkrug, R.; Polymeroopoulos, E.T.; Jastroch, M.J. Brown adipose tissue: Physiological function and evolutionary significance. J. Comp. Physiol. B 2015, 185, 587–606. [CrossRef] [PubMed]

119. Blondin, D.P.; Haman, F. Shivering and nonshivering thermogenesis in skeletal muscles. In Thermoregulation: From Basic Neuroscience to Clinical Neurology, Part I; Romanovsky, A.A., Ed.; 3rd Series; Elsevier: Amsterdam, The Netherlands, 2018; Volume 156, pp. 153–173.
120. Berner, N.J.; Grahn, D.A.; Heller, H.C. 8-OH-DPAT-sensitive neurons in the nucleus raphe magnus modulate thermoregulatory output in rats. *Brain Res.* 1999, 831, 155–164. [CrossRef]

121. Hoffman, J.M.; Brown, J.W.; Sirlin, E.A.; Benoit, A.M.; Gill, W.H.; Harris, M.B.; Darnall, R.A. Activation of 5-HT1A receptors in the paragigantocellularis lateralis decreases shivering during cooling in the conscious piglet. *Am. J. Physiol. Regul. Integr. Comp. Physiol.* 2007, 293, R518–R527. [CrossRef]

122. Brown, J.W.; Sirlin, E.A.; Benoit, A.M.; Hoffman, J.M.; Darnall, R.A. Activation of 5-HT1A receptors in medullary raphe disrupts sleep and decreases shivering during cooling in the conscious piglet. *Am. J. Physiol. Regul. Integr. Comp. Physiol.* 2008, 294, R884–R894. [CrossRef]

123. Oerther, S. Temperature set-point changes induced by DA D2/3 and 5-HT1A receptor agonists in the rat. *Neuroreport* 2000, 11, 3949–3951. [CrossRef] [PubMed]

124. Madden, C.J.; Morrison, S.F. Brown adipose tissue sympathetic nerve activity is potentiated by activation of 5-hydroxytryptamine (5-HT)1A/5-HT7 receptors in the rat spinal cord. *Neuropharmacology* 2008, 54, 487–496. [CrossRef]

125. Madden, C.J.; Morrison, S.F. Endogenous activation of spinal 5-hydroxytryptamine (5-HT) receptors contributes to the thermoregulatory activation of brown adipose tissue. *Am. J. Physiol. Regul. Integr. Comp. Physiol.* 2010, 298, R776–R783. [CrossRef] [PubMed]

126. Voronova, I.P.; Kulikov, A.V.; Popova, N.K.; Kozyrev, T.V. Expression of the 1a and 2a serotonin receptor genes in the brain of rats adapted to warm and cold. *J. Thermal Biol.* 2007, 32, 188–192. [CrossRef]

127. Hart, J.S. Insulative and metabolic adaptations to cold in vertebrates. *Symp. Soc. Exp. Biol.* 1964, 18, 31–48. [PubMed]

128. Werner, J.; Schingnitz, G.; Hensel, H. Influence of cold adaptation on the activity of thermoresponsive neurons in thalamus and midbrain of the rat. *Pflugers Arch.* 1981, 391, 327–330. [CrossRef] [PubMed]

129. Kozyrev, T.V.; Pierau, F.-K. Effect of cold adaptation and noradrenaline on thermosensitivity of rat hypothalamic neuron studied In Vitro. *Neurophysiology* 1994, 26, 142–146. [CrossRef]

130. Kozyrev, T.V. Neurophysiological aspects of the long-term adaptation to cold in mammals: The role of central and peripheral thermoreceptors. *J. Therm. Biol.* 2006, 31, 105–114. [CrossRef]

131. Hori, T.; Nakayama, T. Effects of biogenic amines on central thermo-sensory neurones in the rabbit. *J. Physiol.* 1973, 232, 71–85. [CrossRef]

132. Berner, N.J.; Grahn, D.A.; Heller, H.C. 8-OH-DPAT-sensitive neurons in the nucleus raphe magnus modulate thermoregulatory activation of brown adipose tissue. *Am. J. Physiol. Regul. Integr. Comp. Physiol.* 2008, 294, R884–R894. [CrossRef]

133. Oerther, S. Temperature set-point changes induced by DA D2/3 and 5-HT1A receptor agonists in the rat. *Neuroreport* 2000, 11, 3949–3951. [CrossRef] [PubMed]

134. Nason, M.W., Jr.; Mason, P.J. Medullary raphe neurons facilitate brown adipose tissue activation. *J. Neurosci.* 2006, 26, 1190–1198. [CrossRef]

135. Naumenko, V.S.; Tkachev, S.E.; Kulikov, A.V.; Semenova, T.P.; Amerhanov, Z.G.; Smirnova, N.P.; Popova, N.K. The Brain 5-HT1A Receptor Gene Expression in Hibernation. *Genes Brain Behav.* 2008, 7, 300–305. [CrossRef]

136. Kalabukhov, N.I. Sympathy Mlekopitatuyushchikh (Hibernation in Mammals); Nauka: Moscow, Russia, 1985; p. 248.

137. Kusserow, H.; Davies, B.; Hfrtnagl, H.; Voigt, I.; Stroh, T.; Bert, B.; Deng, D.R.; Fink, H.; Veh, R.W.; Theuring, F. Reduced anxiety-related behaviour in transgenic mice overexpressing serotonin 1A receptors. *Mol. Brain Res.* 2004, 129, 104–116. [CrossRef]

138. Nason, M.W., Jr.; Mason, P.J. Medullary raphe neurons facilitate brown adipose tissue activation. *J. Neurosci.* 2006, 26, 1190–1198. [CrossRef]

139. Hart, J.S. Insulative and metabolic adaptations to cold in vertebrates. *Symp. Soc. Exp. Biol.* 1964, 18, 31–48. [PubMed]

140. Watanabe, T.; Morimoto, A.; Murakami, N. Effect of amine on temperature-responsive neuron in slice preparation of rat brain stem. *Am. J. Physiol.* 1986, 250, R553–R559. [CrossRef]

141. Ulhoa, M.A.; da Silva, N.F.; Pires, J.G.; Futuro Neto Hde, A. Raphe obscurus neurons participate in thermoregulation in rats. *Arq. Neuropsiquiatr.* 2013, 71, 249–253. [CrossRef]

142. Watanabe, T.; Morimoto, A.; Murakami, N. Effect of amine on temperature-responsive neuron in slice preparation of rat brain stem. *Am. J. Physiol.* 1986, 250, R553–R559. [CrossRef]

143. Kusserow, H.; Davies, B.; Hfrtnagl, H.; Voigt, I.; Stroh, T.; Bert, B.; Deng, D.R.; Fink, H.; Veh, R.W.; Theuring, F. Reduced anxiety-related behaviour in transgenic mice overexpressing serotonin 1A receptors. *Mol. Brain Res.* 2004, 129, 104–116. [CrossRef]

144. Hoffmann, B.J.; Mezey, E. Distribution of serotonin 5-HT1C receptor mRNA in adult rat brain. *FEBS Lett.* 1989, 247, 453–462. [CrossRef]

145. Molineaux, S.M.; Jessell, T.M.; Axel, R.; Julius, D. 5-HT1C receptor is a prominent serotonin receptor subtype in the central nervous system. *Proc. Natl. Acad. Sci. USA* 1999, 86, 6793–6797. [CrossRef]

146. Mengod, G.; Nguyen, H.; Le, H.; Waerbe, C.; Lübbert, H.; Palacios, J.M. The distribution and cellular localization of the serotonin 1C receptor mRNA in the rodent brain examined by in situ hybridization histochemistry. Comparison with receptor binding distribution. *Neuroscience* 1990, 35, 577–591.

147. Yadav, V.K.; Oury, F.; Suda, N.; Liu, Z.-W.; Gao, X.-B.; Confavreux, C.; Klemenhagen, K.C.; Tanaka, K.F.; Gingrich, J.A.; Guo, X.E.; et al. Leptin regulation of bone mass, appetite and energy expenditure relies on its ability to inhibit serotonin synthesis in the brainstem. *Cell 2009*, 138, 976–989. [CrossRef]

148. Bonaventure, P.; Guo, H.; Tian, B.; Liu, X.; Bittner, A.; Roland, B.; Salunga, R.; Ma, X.J.; Kamme, F.; Meurers, B.; et al. Nuclei and subnuclei gene expression profiling in mammalian brain. *Brain Res.* 2002, 943, 38–47. [CrossRef]
175. Morishima, Y.; Shibano, T. Evidence that 5-HT_{2A} receptors are not involved in 5-HT-mediated thermoregulation in mice. *Pharmacol. Biochem. Behav.* 1995, 52, 755–758. [CrossRef]

176. Fox, M.A.; French, H.T.; LaPorte, J.L.; Blackler, A.R.; Murphy, D.L. The serotonin 5-HT_{2A} receptor antagonist TCB-2: A behavioral and neurophysiological analysis. *Psychopharmacology* 2010, 212, 13–23. [CrossRef] [PubMed]

177. Voronova, I.P.; Khramova, G.M.; Kulikova, E.A.; Petrovskii, D.V.; Bazovkina, D.V.; Kulikov, A.V. 5-HT_{2A} receptors control body temperature in mice during LPS-induced inflammation via regulation of NO production. *Pharmacol. Res.* 2016, 103, 123–131. [CrossRef] [PubMed]

178. Naumenko, V.S.; Bazovkina, D.V.; Kondaurova, E.M. On the Functional Cross-Talk between Brain 5-HT_{2A} and 5-HT_{2C} Receptors. *Zhurnal Vyss. Nervn. Deiatelnosti Im. IP Pavlov.* 2015, 65, 240–247.

179. Buchborn, T.; Lyons, T.; Song, C.; Feilding, A.; Knöpfel, T.J. The serotonin 2A receptor agonist 25CN-NBOH increases murine heart rate and neck-arterial blood flow in a temperature-dependent manner. *J. Psychopharmacol.* 2020, 34, 786–794. [CrossRef]

180. Voronova, I.; Khramova, G.; Bazovkina, D.; Kulikov, A. Involvement of serotonin2A (5-HT_{2A}) receptor and terminal fragment of chromosome 13 in the development of hypothermia in lipopolysaccharide (LPS)-treated mice. *Eur. Neuropsychopharmacol.* 2019, 29, e277. [CrossRef]

181. Dalpiaz, A.; Gessi, S.; Borea, P.A.; Gilli, G. Binding thermodynamics of serotonin to rat-brain 5-HT_{2A} receptors. *Life Sci.* 1995, 57, PL141–PL146. [CrossRef]

182. Sugimoto, Y.; Yamada, J.; Horisaka, K. Activation of peripheral serotonin 2 receptors induces hypothermia in mice. *Life Sci.* 1991, 48, 419–423. [CrossRef]

183. Otsuka, Y.; Blessing, W.W. Spinal 5-HT_{2A} receptors regulate cutaneous sympathetic vasomotor outflow in rabbits and rats; relevance for cutaneous vasconstriction elicited by MDMA (3,4-methylenedioxymethamphetamine, “Ecstasy”) and its reversal by clozapine. *Brain Res.* 2004, 1014, 34–44. [CrossRef]

184. Naitanda, A.; Yasunami, N.; Tokumo, K.; Fujii, H.; Hirai, T.; Nishio, H. Contribution of the peripheral 5-HT_{2A} receptor to mechanical hyperalgesia in a rat model of neuropathic pain. *Neurochem. Int.* 2005, 47, 394–400. [CrossRef]

185. Nonogaki, K.; Nozue, K.; Oka, Y. Increased hypothalamic 5-HT_{2A} receptor gene expression and effects of pharmacologic 5-HT_{2A} receptor inactivation in obese A^+/+ mice. *Biochem. Biophys. Res. Commun.* 2006, 351, 1078–1082. [CrossRef]

186. Saitoh, Y. Suppression of Central post–stroke pain with sarpogrelate hydrochloride and paroxetine. *Pain Res.* 2012, 27, 1–6. [CrossRef]

187. Crane, J.D.; Palanivel, R.; Mottillo, E.; Bujak, A.L.; Wang, H.; Ford, R.J.; Collins, A.; Blümer, R.M.; Fullerton, M.D.; Yabut, J.M.; et al. Inhibiting peripheral serotonin synthesis reduces obesity and metabolic dysfunction by promoting brown adipose tissue thermogenesis. *Nat. Med.* 2015, 21, 166–172. [CrossRef]

188. Otsuka, Y.; Blessing, W.W. Activation of slowly conducting medullary raphe-spinal neurons, including serotonergic neurons, by the ligand TCB-2: A behavioral and neurophysiological analysis. *Neurosci. Res.* 2005, 50, 288, R909–R918. [CrossRef]

189. Otsuka, Y.; Blessing, W.W.; Nalivaiko, E. Selective blockade of 5-HT_{2A} receptors attenuates the increased temperature response in brown adipose tissue to restraint stress in rats. *Stress* 2008, 11, 125–133. [CrossRef]

190. Beig, M.I.; Baumert, M.; Walker, F.R.; Day, T.A.; Nalivaiko, E. Blockade of 5-HT_{2A} receptors suppresses hyperthermic but not cardiovascular responses to psychosocial stress in rats. *Neuroscience* 2009, 159, 1185–1191. [CrossRef]

191. Sinh, V.; Otsuka, Y. Blockade of 5-HT_{2A} receptors inhibits emotional hyperthermia in mice. *J. Physiol. Sci.* 2019, 69, 1097–1102. [CrossRef]

192. Buckholtz, N.S.; Zhou, D.F.; Freedman, D.X. Serotonin2 agonist administration down-regulates rat brain serotonin2 receptors. *Life Sci.* 1988, 42, 2439–2445. [CrossRef]

193. Lam, D.D.; Przydzial, M.J.; Ridley, S.H.; Yeo, G.S.H.; Rochford, J.J.; O’Rahilly, S.; Heisler, L.K. Serotonin 5-HT_{2C} receptor agonist promotes hypoglycemia via downstream activation of melanocortin4 Receptors. *Endocrinology* 2008, 149, 1323–1328. [CrossRef] [PubMed]

194. Berger, M.; Gray, J.A.; Roth, B.L. The Expanded Biology of Serotonin. *Annu. Rev. Med.* 2009, 60, 355–366. [CrossRef] [PubMed]

195. Sohle, J.; Machuy, N.; Smajilbegovic, E.; Holtzmann, U.; Gronninger, E.; Wencik, H.; Stab, F.; Winnefeld, F. Identification of new genes involved in human adipogenesis and fat storage. *PLoS ONE* 2012, 7, e31193. [CrossRef]

196. Oh, C.-M.; Namkung, J.; Go, Y.; Shong, K.E.; Kim, K.; Kim, H.; Park, B.-Y.; Lee, H.W.; Jeon, Y.H.; Song, J.; et al. Regulation of systemic energy homeostasis by serotonin in adipose tissues. *Nat. Commun.* 2015, 6, 1–12. [CrossRef] [PubMed]

197. Stunes, A.K.; Reseland, J.E.; Hauso, Ø.; Kidd, M.; Tomter, K.; Waldum, H.L.; Syversen, U.; Gustafsson, B.I. Adipocytes express 5-HT_{2A} receptor signaling. *FASEB J.* 2003, 17, 1373–1375. [CrossRef] [PubMed]

198. Harmon, J.L.; Wills, L.P.; McOmish, C.E.; Demireva, E.Y.; Gingrich, J.A.; Beeson, C.C.; Schnellmann, R.G. 5-HT_{2A} receptor regulation of mitochondrial genes: Unexpected pharmacological effects of agonists and antagonists. *J. Pharmacol. Exp. Ther.* 2016, 357, 1–9. [CrossRef]
Biomolecules 2021, 11, 1914

201. Bouillaud, F.; Alves-Guerra, M.C.; Ricquier, D. UCPs, at the interface between bioenergetics and metabolism. Biochim. Biophys. Acta. 2016, 1863, 2443–2456. [CrossRef] [PubMed]

202. Derkach, V.; Surprenant, A.; North, R.A. 5-HT3 receptors are membrane ion channels. Nature 1989, 339, 706–709. [CrossRef] [PubMed]

203. Lummis, S.C.R. 5-HT3 Receptors. J. Biol. Chem. 2012, 287, 40239–40245. [CrossRef] [PubMed]

204. Thompson, A.A.; Lummis, S.C.R. Discriminating between 5-HT3 receptors: A therapeutic target. Expert Opin. Ther. Targets 2007, 11, 527–540. [CrossRef]

205. Thompson, A.J.; Lummis, S.C. The 5-HT3 receptor—the relationship between structure and function. Neuropharmacology 2009, 56, 273–284. [CrossRef] [PubMed]

206. Thompson, A.J.; Lummis, S.C. The 5-HT3 receptor. Curr. Pharm. Des. 2006, 12, 3615–3630. [CrossRef] [PubMed]

207. Lummis, S.C.R. 5-HT3 receptors. Drug Discov. Today 2005, 10, 8547–8551. [CrossRef]

208. Bouillaud, F.; Alves-Guerra, M.C.; Ricquier, D. UCPs, at the interface between bioenergetics and metabolism. Biochim. Biophys. Acta. 2016, 1863, 2443–2456. [CrossRef] [PubMed]

209. Maricq, A.V.; Peterson, A.S.; Brake, A.J.; Myers, R.M.; Julius, D. Primary structure and function of the 5-HT3 receptor, a serotonin-gated ion channel. Science 1991, 254, 432–437. [CrossRef]

210. Thompson, A.J.; Lummis, S.C. The 5-HT3 receptor. Curr. Pharm. Des. 2006, 12, 3615–3630. [CrossRef] [PubMed]

211. Thompson, A.J.; Lummis, S.C. The 5-HT3 receptor as a therapeutic target. Expert Opin. Ther. Targets 2007, 11, 527–540. [CrossRef]

212. Thompson, A.J.; Lummis, S.C. Discriminating between 5-HT3A and 5-HT3B receptors. Br. J. Pharmacol. 2013, 169, 736–747. [CrossRef]

213. Boyd, G.W.; Doward, A.I.; Kirkness, E.F.; Millar, N.S.; Connolly, C.N. Cell surface expression of 5-hydroxytryptamine type 3 receptors is controlled by an endoplasmic reticulum retention signal. J. Biol. Chem. 2003, 278, 27681–27687. [CrossRef]

214. Martin, S.M.; Wilson, B.C.; Chen, X.; Takahashi, Y.; Poulin, P.; Pittman, Q.J. Vagal CCK and 5-HT3C receptor antagonists for the prevention of perioperative shivering: A systematic review and meta-analysis of randomised controlled trials. BMJ Open 2020, 10, e038293. [CrossRef] [PubMed]

215. Refinetti, R. Peripheral nervous control of cold-induced reduction in the respiratory quotient of the rat. Int. J. Biometeorol. 1990, 34, 24–27. [CrossRef]

216. Tkachenko, E.Y.; Kozaruk, V.P.; Khramova, G.M.; Voronova, I.P.; Meyta, E.S.; Kozyreva, T.V. Different formation of thermoregulatory responses to cooling in dependence on the type of the skin thermoreceptor activity. Bull. Sib. Branch Russ. Acad. Med. Sci. 2010, 30, 95–100.

217. Wang, W.; Song, X.; Wang, T.; Zhang, C.; Sun, L. 5-HT3 receptor antagonists for the prevention of perioperative shivering: A meta-analysis. J. Clin. Pharmacol. 2017, 57, 428–439. [CrossRef]

218. Shang, Z.-H.; Li, H.-F.; Zhou, X.; Lu, Y.; Yuan, X.-Z. 5-HT3 receptor antagonists for the prevention of perioperative shivering undergoing spinal anaesthesia: A systematic review and meta-analysis of randomised controlled trials. BMJ Open 2020, 10, e038293. [CrossRef] [PubMed]

219. Ruat, M.; Traiffort, E.; Leurs, R.; Tardivel-Lacombe, J.; Diaz, J.; Arrang, J.M.; Schwartz, J.C. Molecular cloning, characterization, and localization of a high-affinity serotonin receptor (5-HT7) activating cAMP formation. Proc. Natl. Acad. Sci. USA 1993, 90, 8547–8551. [CrossRef]

220. Lovenberg, T.W.; Baron, B.M.; de Leece, L.A.; Miller, J.D.; Prosser, R.A.; Rea, M.A.; Foye, P.E.; Racke, M.; Slone, A.L.; Siegel, B.W.; et al. A novel adenylyl cyclase-activating serotonin receptor (5-HT7) implicated in the regulation of mammalian circadian rhythms. Neuroreport 1993, 13, 449–458. [CrossRef]

221. Bard, J.A.; Zgombick, J.; Adham, N.; Vaysses, P.; Branchek, T.A.; Weinshank, R.L. Cloning of a novel human serotonin receptor (5-HT7) positively linked to adenylyl cyclase. J. Biol. Chem. 1993, 268, 23422–23426. [CrossRef]
229. Hedlund, P.B.; Sutcliffe, J.G. Functional, molecular and pharmacological advances in 5-HT\textsubscript{7} receptor research. *Trends Pharmacol. Sci.* 2004, 25, 481–486. [CrossRef]  
230. Gellynck, E.; Heyninck, K.; Andressen, K.W.; Haegeman, G.; Levy, F.O.; Vanhoenacker, P.; Van Craenenbroeck, K. The serotonin 5-HT\textsubscript{1A} receptors: Two decades of research. *Exp. Brain Res.* 2013, 230, 555–568. [CrossRef]  
231. Nikiforuk, A. Targeting the serotonin 5-HT\textsubscript{7} receptor in the search for treatments for CNS disorders: Rationale and progress to date. *CNS Drugs* 2015, 29, 265–275. [CrossRef] [PubMed]  
232. Heidmann, D.E.; Metcalf, M.A.; Kohen, R.; Hamblin, M.W. Four 5-hydroxytryptamine\textsubscript{7} (5-HT\textsubscript{7}) receptor isoforms in human and rat produced by alternative splicing: Species differences due to altered intron-exon organization. *J. Neurochem.* 1997, 68, 1372–1381. [CrossRef] [PubMed]  
233. Olsen, M.A.; Schechter, L.E. Cloning, mRNA localization and evolutionary conservation of a human 5-HT\textsubscript{7} receptor pseudogene. *Gene* 1999, 227, 63–69. [CrossRef]  
234. Leopoldo, M.; Lacivita, E.; Berardi, F.; Perrone, R.; Hedlund, P.B. Serotonin 5-HT\textsubscript{7} receptor agents: Structure-activity relationships and potential therapeutic applications in central nervous system disorders. *Pharmacol. Ther.* 2011, 129, 120–148. [CrossRef]  
235. Matthys, A.; Haegeman, G.; Van Craenenbroeck, K. Role of the 5-HT\textsubscript{7} receptor in nociception. *J. Neurosci.* 2004, 24, 1372–1381. [CrossRef] [PubMed]  
236. Guseva, D.; Wirth, A.; Ponimaskin, E. Cellular mechanisms of the 5-HT\textsubscript{7} receptor. *Adv. Pharmacol. Sci.* 2012, 4, 228–249. [CrossRef]  
237. Klein, E.; Egan, G.; Cook, G.P.; Stanton, J.A.; Beer, M.S.; Rosahl, T.W.; Hartmann, S.; Kulagowski, J.; McAllister, G.; Fone, K.C.F.; et al. The hypothymic effect of 5-CT in mice is mediated through the 5-HT\textsubscript{7} receptor. *Neuropharmacology* 2003, 44, 1031–1037. [CrossRef]  
238. Hrvatin, S.; Sun, S.; Wilcox, O.F.; Yao, H.; Lavin-Peter, A.J.; Cicconet, M.; Assad, E.G.; Palmer, M.E.; Aronson, S.; Banks, A.S.; et al. Selective agonists for serotonin 5-HT\textsubscript{7} receptor and their applications in preclinical models: An overview. *Rev. Neuosci.* 2014, 25, 401–415. [CrossRef]  
239. Yamada, J.; Sugimoto, Y.; Wakita, H.; Horisaka, K. The involvement of serotonergic and dopaminergic systems in hypothermia induced in mice by intracerebroventricular injection of serotonin. *Jpn. J. Pharmacol.* 1988, 48, 145–148. [CrossRef] [PubMed]  
240. Kose, D.; Cadirci, E.; Halici, Z.; Sirin, B.; Dincer, B. The investigation of possible roles of central 5-HT\textsubscript{7} receptors in antiyptic effect mechanism of paracetamol in LPS-induced hyperthermia model of mice. *Inflammopharmacology* 2019. [CrossRef]  
241. Faurre, C.; Mnie-Filali, O.; Scarna, H.; Debonnel, G.; Haddjeri, N. Effects of the 5-HT\textsubscript{7} receptor antagonist SB-269970A on rat hormonal and temperature responses to the 5-HT\textsubscript{1A/7} receptor agonist 8-OH-DPAT. *Neurosci. Lett.* 2006, 404, 122–126. [CrossRef] [PubMed]  
242. Di Pilato, P.; Niso, M.; Adriani, W.; Romano, E.; Travaglini, D.; Berardi, F.; Colabufo, N.A.; Perrone, R. LP-211 is a brain penetrant selective agonist for the serotonin 5-HT\textsubscript{7} receptor. *Brain Res.* 2011, 1481, 12–16. [CrossRef]  
243. Brenchat, A.; Rocosalbas, M.; Zamaniolo, D.; Hamon, M.; Vela, J.M.; Romero, L. Assessment of 5-HT\textsubscript{7} receptor agonists selectivity using nociceptive and thermoregulation tests in knockout versus wild-type mice. *Adv. Pharmacol. Sci.* 2012, 2012, 312041. [CrossRef]  
244. Van Wimersma Greidanus, T.B.; Evers, J.; van den Burg, M.; Romano, E.; Travaglini, D.; Berardi, F.; Colabufo, N.A.; Perrone, R.; Laviola, G.; Lacivita, E.; et al. Characterization of SB-269970-A, a selective 5-HT\textsubscript{7} receptor antagonist. *Exp. Brain Res.* 2013, 235, 235–248. [CrossRef] [PubMed]  
245. Faure, C.; Mnie-Filali, O.; Scarna, H.; Debonnel, G.; Haddjeri, N. Effects of the 5-HT\textsubscript{7} receptor antagonist SB-269970A on rat hormonal and temperature responses to the 5-HT\textsubscript{1A/7} receptor agonist 8-OH-DPAT. *Neurosci. Lett.* 2006, 404, 122–126. [CrossRef] [PubMed]  
246. Di Pilato, P.; Niso, M.; Adriani, W.; Romano, E.; Travaglini, D.; Berardi, F.; Colabufo, N.A.; Perrone, R.; Laviola, G.; Lacivita, E.; et al. Characterization of SB-269970-A, a selective 5-HT\textsubscript{7} receptor antagonist. *Exp. Brain Res.* 2013, 235, 235–248. [CrossRef] [PubMed]  
247. Yamada, J.; Sugimoto, Y.; Wakita, H.; Horisaka, K. The involvement of serotonergic and dopaminergic systems in hypothermia induced in mice by intracerebroventricular injection of serotonin. *Jpn. J. Pharmacol.* 1988, 48, 145–148. [CrossRef] [PubMed]  
248. Kose, D.; Cadirci, E.; Halici, Z.; Sirin, B.; Dincer, B. The investigation of possible roles of central 5-HT\textsubscript{7} receptors in antipyretic effect mechanism of paracetamol in LPS-induced hyperthermia model of mice. *Inflammopharmacology* 2019. [CrossRef]  
249. Gargaglioni, L.H.; Steiner, A.A.; Branco, L.G.S. Involvement of serotonergic receptors in the anteroverentral preoptic region on hypoxia-induced hypothermia. *Brain Res.* 2015, 1644, 104–122. [CrossRef]  
250. hrvatin, S.; Sun, S.; Wilcox, O.F.; Yao, H.; Lavin-Peter, A.J.; Cicconet, M.; Assad, E.G.; Palmer, M.E.; Aronson, S.; Banks, A.S.; et al. Neurons that regulate mouse thirst. *Nature Res.* 2020, 583, 115–121. [CrossRef] [PubMed]  
251. Sugiura, T.; Bielefeldt, K.; Gebhart, G.F. TRPV1 function in mouse colon sensory neurons is enhanced by metabotropic 5-hydroxytryptamine receptor activation. *J. Neurosci.* 2004, 24, 9521–9530. [CrossRef] [PubMed]  
252. Kayser, V.; Elfassi, I.E.; Aubel, B.; Melfort, M.; Julius, J.D.; Gingrich, A.; Hamon, M.; Bourgois, S. Mechanical, thermal and formalin-induced nociception is differentially altered in 5-HT\textsubscript{1A/-}, 5-HT\textsubscript{1B/-}, 5-HT\textsubscript{2A/-}, 5-HT\textsubscript{3A/-} and 5-HT\textsubscript{7/-} knock-out male mice. *Pain* 2007, 130, 235–248. [CrossRef]  
253. Kapers, R.; Frokjaer, V.G.; Naert, A.; Christensen, R.; Budtz-Jørgensen, E.; Kehlet, H.; Knudsen, G.M. A PET [18F]altanserin study of 5-HT\textsubscript{7} receptor binding in the human brain and responses to painful heat stimulation. *Neuroimage* 2009, 44, 1001–1007. [CrossRef] [PubMed]
254. Brenchat, A.; Romero, L.; García, M.; Pujol, M.; Burgueño, J.; Torrens, A.; Hamon, M.; Baeyens, J.M.; Buschmann, H.; Zamanillo, D.; et al. 5-HT7 receptor activation inhibits mechanical hypersensitivity secondary to capsaicin sensitization in mice. *Pain* **2009**, *141*, 239–247. [CrossRef]

255. Cortés-Altamirano, J.L.; Olmos-Hernández, A.; Jaime, H.B.; Carrillo-Mora, P.; Bandala, C.; Reyes-Long, S.; Alfaro-Rodríguez, A. 5-HT1, 5-HT2, 5-HT3 and 5-HT7 receptors and their role in the modulation of pain response in the central nervous system. *Curr. Neuropharmacol.* **2018**, *16*, 210–221. [CrossRef]

256. Nagai, M. The role of serotonergic system in body temperature regulation. *Physiol. Res.* **1992**, *41*, 65–69.

257. Uphouse, L. Multiple serotonin receptors: Too many, not enough, or just the right number? *Neurosci. Biobehav. Rev.* **1997**, *21*, 679–698. [CrossRef]

258. Zhang, Y.; D’Souza, D.; Raap, D.K.; Garcia, F.; Battaglia, G.; Muma, N.A.; Van de Kar, L.D. Characterization of the functional heterologous desensitization of hypothalamic 5-HT1A receptors after 5-HT2A receptor activation. *J. Neurosci.* **2001**, *21*, 7919–7927. [CrossRef]

259. Zhang, Y.; Gray, T.S.; D’Souza, D.N.; Carrasco, G.A.; Damjanoska, K.J.; Dudas, B.; Garcia, F.; Zainelli, G.M.; Hanley, N.R.S.; Battaglia, G.; et al. Desensitization of 5-HT1A receptors by 5-HT2A receptors in neuroendocrine neurons In Vivo. *J. Pharmacol. Exp. Ther.* **2004**, *310*, 59–66. [CrossRef]

260. Ishiwata, T.; Hasegawac, H.; Greenwood, B.N. Involvement of serotonin in the ventral tegmental area in thermoregulation of freely moving rats. *Neurosci. Lett.* **2017**, *653*, 71–77. [CrossRef]

261. Burton, A.C.; Edholm, O.G. *Man in A Cold Environment. Physiological and Pathological Effects of Exposure to Low Temperatures*; Edward Arnold Ltd.: London, UK, 1955; p. 273.

262. Gordon, C.J. The therapeutic potential of regulated hypothermia. *Emerg. Med. J.* **2001**, *18*, 81–89. [CrossRef] [PubMed]

263. Johansen, F.F.; Hasseldam, H.; Smith, M.N.; Rasmussen, R.S. Drug-induced hypothermia by SHT1A agonists provide neuroprotection in experimental stroke: New perspectives for acute patient treatment. *J. Stroke Cerebrovasc. Dis.* **2014**, *23*, 2879–2887. [CrossRef] [PubMed]

264. Tarahovsky, Y.S.; Fadeeva, I.S.; Komelina, N.P.; Khrenov, M.O.; Zakharova, N.M. Antipsychotic inductors of brain hypothermia and torpor-like states: Perspectives of application. *Psychopharmacology* **2016**, *234*, 173–184. [CrossRef] [PubMed]

265. Puspitasari, A.; Cerri, M.; Takahashi, A.; Yoshida, Y.; Hanamura, K.; Tinganelli, W. Hibernation as a tool for radiation protection in space exploration. *Life* **2021**, *11*, 54. [CrossRef]